Absorbent article
By using urease inhibitors and polyols in absorbent products, the skin irritation problems caused by absorbent products are solved, the urine absorption efficiency is improved, the incidence of diaper rash is reduced, and skin health is improved.
Patent Information
- Application Number
- CN202380039170.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-05-16
- Filing Date
- 2023-05-09
- Publication Date
- 2024-12-06
AI Technical Summary
Existing absorbent products are prone to skin irritation during use, especially diaper rash, which is mainly due to high humidity and poor urine absorption, which affects skin health.
The product is assembled using an absorbent article containing a urease inhibitor and a polyol by suspending or dissolving the urease inhibitor in the polyol and applying it to a liquid permeable topsheet, absorbent core and acquisition and dispensing layer. , to reduce the residence time of urine on the topsheet and improve absorption efficiency.
Effectively reduce the possibility of diaper rash, improve the wearer's skin health, reduce the time of urine on the topsheet and improve the absorption efficiency, reduce the formation of ammonia caused by urea decomposition, and keep the skin pH within the appropriate range.
Smart Images

Figure CN119095563A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to an absorbent article comprising a urease inhibitor and a polyol. The present invention also relates to a method for manufacturing an absorbent article, the method comprising the steps of suspending and / or dissolving the urease inhibitor in the polyol; applying the suspension and / or solution to one or more of a liquid permeable top sheet, an absorbent core and at least one acquisition and distribution layer, and assembling the article. Background Art
[0002] Absorbent articles such as diapers and pants are well known. Although their use is widely accepted, some wearers or caregivers are concerned about skin health when using such articles. Skin irritation associated with absorbent articles is often referred to as "diaper rash." Especially for the delicate skin of infants, skin health is very important. However, skin health is often a focus for many consumers, and this is also true when absorbent articles are used for toddlers and adults.
[0003] Skin irritation may be caused in particular by high levels of moisture within the absorbent article during use and by urine and feces deposited within the absorbent article. Therefore, the likelihood of skin irritation increases with the length of time that the absorbent article is worn.
[0004] A known method of addressing and improving skin health is to apply a lotion to the body-facing surface of the top sheet of an absorbent article. Such lotions typically contain skin care components. During use of the article, at least a portion of the lotion is intended to transfer to the wearer's skin to provide some degree of protection against skin irritation.
[0005] However, due to its typical hydrophobicity, the application of lotion on the top sheet of absorbent article may adversely affect the collection of liquid (such as urine) through the top sheet. In addition, during use or even during the storage of the absorbent article before use, especially at higher temperatures, a part of lotion may migrate into the absorbent article through the top sheet. Once inside the absorbent article, lotion can further adversely affect the suitable collection and storage of urine, for example, in the absorbent material of absorbent core. Therefore, using lotion or other (hydrophobic) materials on the body-facing surface of the top sheet can not only have a positive effect on skin care, but also may produce some negative effects on skin health, for example, by extending the time that urine stays on the top sheet before being absorbed through the top sheet, or by slowing down the collection of liquid and the storage inside the absorbent article.
[0006] Thus, there remains a need for absorbent articles that can help reduce the likelihood of diaper rash. Summary of the invention
[0007] The present invention relates to an absorbent article, comprising:
[0008] - Liquid permeable topsheet,
[0009] - a liquid-impermeable backsheet,
[0010] - an absorbent core, and
[0011] - Optionally at least one acquisition and distribution layer.
[0012] The absorbent core is disposed between the topsheet and the backsheet; and the optional at least one acquisition and distribution layer is disposed between the topsheet and the absorbent core.
[0013] The absorbent article comprises a polyol and a urease inhibitor.
[0014] The present invention also relates to a method for manufacturing an absorbent article, the method comprising the following steps
[0015] a) suspending and / or dissolving a urease inhibitor in a polyol to form a suspension and / or solution comprising the urease inhibitor and the polyol;
[0016] b) applying the suspension and / or solution to one or more of the following:
[0017] - a liquid permeable top sheet (26),
[0018] - an absorbent core (30), and
[0019] - at least one acquisition and distribution layer (38);
[0020] c) assembling the absorbent article (10) such that the absorbent core (30) is disposed between the top sheet (26) and the back sheet (28); and the at least one optional acquisition and distribution layer (38) is disposed between the top sheet (26) and the absorbent core (30).
[0021] Absorbent articles comprising a polyol and a urease inhibitor and absorbent articles obtainable by the process of the present invention help improve the skin health of the wearer and thus reduce the likelihood of diaper rash. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] The above and other features and advantages of the present disclosure and the manner in which they are obtained will become more apparent, and the present disclosure itself will be better understood, by referring to the following description of example forms of the present disclosure made in conjunction with the accompanying drawings, in which:
[0023] Figure 1 is a plan view of an exemplary absorbent article in the form of a taped diaper, with the garment-facing surface facing the viewer, in a flat, unfolded condition;
[0024] Figure 2for Figure 1 A plan view of an example absorbent article of the invention, with the body-facing surface facing the viewer, in a flat, unfolded state;
[0025] Figure 3 For the fastened position Figure 1 and Figure 2 A front perspective view of an absorbent article;
[0026] Figure 4 is a front perspective view of an absorbent article in the form of a pant;
[0027] Figure 5 for Figure 4 a back perspective view of an absorbent article;
[0028] Figure 6 for Figure 4 a plan view of an absorbent article of the type shown in FIG. 1 , the absorbent article being laid flat with the garment-facing surface facing the viewer;
[0029] Figure 7 Taken along line 7-7 Figure 6 A cross-sectional view of an absorbent article;
[0030] Figure 8 Taken along line 8-8 Figure 6 A cross-sectional view of an absorbent article;
[0031] Fig. 9 is a plan view of an exemplary absorbent core or absorbent article;
[0032] Fig.10 Taken along line 10-10 Fig. 9 A cross-sectional view of an absorbent core;
[0033] Fig.11 Taken along line 11-11 Fig.10 A cross-sectional view of an absorbent core;
[0034] Fig.12 is a plan view of an exemplary absorbent article of the present disclosure that is a sanitary napkin;
[0035] Fig.13 is an exemplary cross-sectional view taken within the front waist region of an absorbent article;
[0036] Fig.14 is an exemplary cross-sectional view taken within the crotch region of an absorbent article;
[0037] Fig.15 is an exemplary cross-sectional view taken within the rear waist region of an absorbent article;
[0038] Fig.16 An apparatus for improving fluid collection testing is shown;
[0039] Fig.17A is a side view of a curved component for improved fluid collection testing;
[0040] Fig. 17B for Fig.17A an end view of a curved component;
[0041] Fig. 17C for Fig.17A A bottom view of a curved component;
[0042] Fig.17D for Fig.17A A bottom perspective view of a curved component;
[0043] Fig.17E for Fig.17A A top perspective view of a curved component;
[0044] Fig.18A A top plate assembly for use in improved fluid collection testing is shown;
[0045] Fig.18B An apparatus for improving fluid collection testing is shown;
[0046] Fig.19 Shows the equipment components used for the "Post-harvest Collagen Rewetting Test Method";
[0047] Fig. 20 Shows the equipment components used for the "Fixed Height Frit Absorption (FHFA) Test Method";
[0048] Fig.21 and Fig. 22 A partial schematic diagram showing components of a setup used for the In-Plane Radial Permeability (IPRP) Test described herein. DETAILED DESCRIPTION
[0049] definition
[0050] "Absorbent article" refers to a device that absorbs and contains body exudates, especially urine and other aqueous liquids, and more specifically refers to a device that is placed close to or adjacent to the wearer's body to absorb and contain various exudates discharged from the body. Absorbent articles may include diapers (diapers for babies and infants and diapers to solve adult incontinence), pants (pants for babies and infants and pants to solve adult incontinence), disposable absorbent inserts for diapers and pants with reusable outer covers, and female care absorbent products such as sanitary napkins or panty liners. As used herein, the term "exudate" includes, but is not limited to, urine, blood, vaginal secretions, sweat and feces. Preferred absorbent articles of the present invention are diapers, pants and inserts. In addition, preferred absorbent articles of the present invention are disposable absorbent articles, more preferably disposable diapers, disposable pants and disposable absorbent inserts.
[0051] As used herein, "absorbent core" refers to a structure intended to be positioned between the topsheet and the backsheet of an absorbent article for absorbing and storing liquids received by the absorbent article.
[0052] As used herein, "airfelt" refers to comminuted wood pulp in the form of cellulose fibers.
[0053] "Disposable" is used in its ordinary sense to refer to an article that is disposed of or discarded after a limited number of use events (e.g., less than 10 events, less than 5 events, or less than 2 events) over varying lengths of time. If the disposable absorbent article is a diaper, pants, absorbent insert, sanitary napkin, catamenial pad, or wet wipe for personal hygiene, the disposable absorbent article is generally intended to be discarded after a single use. The used and discarded absorbent article may or may not be subsequently recycled.
[0054] "Diapers" and "pants" refer to absorbent articles that are generally worn by infants and incontinent patients around the lower body so as to surround the waist and legs of the wearer and are particularly suitable for receiving and containing urine and feces. In pants, as used herein, the longitudinal edges of the first waist region and the second waist region are attached to each other to preform the waist opening and the leg openings. The pants are worn on the wearer by extending the wearer's legs into the leg openings and pulling the pants absorbent article to a position near the wearer's lower body. Pants can be preformed by any suitable technology, including but not limited to using refastenable and / or non-refastenable bonding (e.g., seams, welding, adhesives, adhesive bonding, fasteners, etc.) to join the parts of the absorbent article together. Pants can be preformed at any position along the periphery of the product (e.g., side fastening, front waist fastening). In diapers, the waist opening and leg openings are only formed when the diaper is worn on the wearer in the following manner: the longitudinal edges of the first waist region and the second waist region are attached to each other (releasably) on both sides with a suitable fastening system.
[0055] "Superabsorbent polymer material" ("SAP" material) is used herein to refer to a cross-linked polymeric material that can absorb at least 7 times its weight of an aqueous 0.9 wt% saline solution, as measured using the "Centrifuge Retention Capacity Test" described below. The superabsorbent polymer material of the present invention contains a polymer that contains acrylic acid and / or acrylic acid esters and / or methacrylic acid and / or methacrylic acid esters as monomer groups. The SAP material is preferably provided in the form of superabsorbent polymer particles (SAP particles) and / or in the form of superabsorbent fibers (SAFs).
[0056] "Superabsorbent polymer particles" ("SAP" particles) are used herein to refer to superabsorbent polymer materials that are in particulate form so as to be flowable in the dry state. Superabsorbent polymer particles are distinguished from the superabsorbent fibers of the present invention in that the ratio of their largest dimension to their smallest dimension is no greater than 10 to 1. The superabsorbent polymer particles may, for example, be in the form of particles, spheres, flakes or agglomerates.
[0057] More than one urease inhibitor may be used in an absorbent article. If more than one urease inhibitor is used, the term "urease inhibitor" or "the urease inhibitor" refers to all urease inhibitors used, unless otherwise expressly stated. Furthermore, if more than one urease inhibitor is used, any amount of urease inhibitors mentioned herein refers to the total amount of all urease inhibitors used, unless otherwise expressly stated.
[0058] Natural urease inhibitors are obtained from natural sources, particularly plant-based sources such as green tea or grape seeds.
[0059] As used herein, the term "nonwoven web" refers to a material that is a fabricated web / layer of oriented or randomly oriented fibers or filaments. The fibers may be of natural or artificial origin. Natural fibers may be selected from the group consisting of wheat straw fibers, rice straw fibers, flax fibers, bamboo fibers, cotton fibers, jute fibers, hemp fibers, sisal fibers, bagasse fibers, yucca fibers, Miscanthus fibers, marine or freshwater algae / seaweed fibers, silk fibers, wool fibers, and combinations thereof. Another group of fibers may also be regenerated cellulose fibers, such as viscose, lyocell fibers, and combinations thereof. ® ), rayon, modal, cellulose acetate fiber, acrylic fiber, cuprammonium rayon, regenerated protein fiber, etc. Preferably, the natural fiber or modified natural fiber is selected from the group consisting of cellulose fiber (also known as pulp or air felt) or modified cellulose fiber (such as cellulose fiber cross-linked within the fiber), cotton fiber, bamboo fiber, viscose fiber or a mixture thereof. More preferably, the natural fiber or modified natural fiber is cellulose fiber or modified cellulose fiber. The synthetic fiber can be selected from the group consisting of polyolefins (such as polyethylene, polypropylene or combinations and mixtures thereof), polyethylene terephthalate (PET), co-PET, polylactic acid (PLA), polybutylene succinate (PBS), polyhydroxyalkanoate (PHA), nylon (or polyamide) or a mixture or combination thereof.
[0060] The fibers in the nonwoven web are consolidated by friction, and / or entanglement, and / or cohesion, and / or adhesion, and / or by thermal bonding, pressure bonding, or heat and pressure bonding, and / or ultrasonic bonding, excluding paper and woven, knitted, tufted, stitched products. The fibers can be short fibers (e.g., in a carded nonwoven web) or continuous fibers (e.g., in a spunbond or meltblown nonwoven fiber).
[0061] The nonwoven web that absorbent core of the present invention comprises can comprise superabsorbent fiber or can be made up of superabsorbent fiber.Nonwoven web can be formed by many processes, such as melt-blowing, spun-fiber web, solvent spinning, electrospinning and carding, and fiber can be for example consolidated by spunlace (in spunlace nonwoven web), air-through bonding (using hot air blowing through fiber layer in thickness direction), infrared heating, acupuncture, one or more bonding patterns and bonding impressions or their combination produced by local compression and / or applying heat or ultrasonic energy.Alternatively or in addition, can consolidate fiber by using binding agent.Binder can provide in the form of binding agent fiber or particle (it melts subsequently), or can provide in liquid form, such as styrene butadiene binding agent.Liquid binding agent is provided to fiber (for example, by spraying, printing or foam application) and solidified subsequently with solidification.
[0062] The basis weight of nonwoven webs is usually expressed in grams per square meter (g / m 2 )express.
[0063] The nonwoven web, in particular the nonwoven web composed of or containing superabsorbent fibers, can be a carded web formed by needling. In needling, the cohesion of the fibers and the interweaving of the fibers with each other are obtained by passing a needle through a moving fiber layer and mixing the fibers with each other. One or more or all nonwoven webs of the absorbent core of the present invention can also be formed by two or more precursor webs, which are combined with each other by a needling process.
[0064] Alternatively, one or more or all of the nonwoven webs of the absorbent core of the present invention can be formed by spunlace. In the spunlace nonwoven web, the fiber has been combed into a precursor web, and then subjected to a spunlace process so that the fibers are interwoven and entangled with each other. The cohesion and interweaving of the fibers can be by means of a plurality of jetted water streams passing through a moving fleece fabric or cloth under pressure, and the fibers are interwoven with each other (hereinafter also referred to as "hydraulic interweaving") like knitting. Therefore, the consolidation of the spunlace nonwoven web is basically the result of hydraulic interweaving. As used herein, "spunlace nonwoven web" also relates to a nonwoven web formed by two or more precursor webs, which are combined with each other by hydraulic interweaving.
[0065] Before two or more webs are combined into one nonwoven by needle punching or hydroentanglement, they may have undergone a bonding process, such as by heat and / or pressure bonding using, for example, patterned calendar rolls and anvil rolls to impart a bonding pattern. However, the two or more webs are only combined with each other by needle punching or hydroentanglement.
[0066] Alternatively, the carded nonwoven web made by needle punching or spunlace is a single nonwoven web, that is, it is not formed by two or more precursor webs. In another alternative, one or more or all nonwoven webs of the nonwoven web of the absorbent core of the present invention can be formed by a precursor web, and staple fibers are laid on the precursor web. Staple fibers can be superabsorbent fibers or can include superabsorbent fibers. Staple fibers may not yet be consolidated into a self-sustaining precursor web, but fibers are loosely laid on the precursor web. Then by (only) needle punching or (only) hydraulic interweaving, relatively loose staple fibers are combined with each other and entangled with the fibers of the following precursor web. The nonwoven layer / web of spunlace and / or needle punching can be made of staple fibers or continuous fibers (continuous fibers are also usually referred to as filaments).
[0067] Through-air bonding refers to a process for bonding short or continuous fibers by forcing air through a nonwoven web, wherein the air is hot enough to melt the polymer of the fibers (or at least partially melt, or melt to a state where the fiber surface becomes sufficiently tacky), or if the fibers are multicomponent fibers, wherein the air is hot enough to melt one of the polymers of the fibers making up the nonwoven web (or at least partially melt, or melt to a state where the fiber surface becomes sufficiently tacky). The melting and resolidification of the polymers provides bonding between the different fibers.
[0068] "Include" or "comprising" are open-ended terms, each specifying the presence of a feature, such as a component, but not excluding the presence of other features, such as elements, steps, components, known in the art or disclosed herein. These terms based on the verb "comprise (include)" encompass the narrower term "consisting essentially of...", which excludes any unmentioned elements, steps or ingredients that significantly affect the way the feature performs its function; and encompass the term "consisting of...", which excludes any unspecified elements, steps or ingredients.
[0069] "Body-facing" (also referred to herein as "skin-facing") and "clothing-facing" refer to the relative positions of the surfaces of an element or element, layer, or component, respectively. "Body-facing" refers to an element or surface that is closer to the wearer than another element of the same component during wear. An example is an absorbent core with a body-facing surface, the body-facing surface being a surface of the absorbent core that is closer to the wearer's body than the relative surface of the absorbent core facing clothes. "Clothing-facing" refers to an element or a surface of an element, layer, or component that is farther away from the wearer than another element or surface of an element, layer, or component or the absorbent article as a whole during wear. The clothing-facing surface may face another (i.e., in addition to the wearable article) garment of the wearer, other articles such as bedding, or the atmosphere. Typically, the body-facing surface of the top sheet forms at least a portion of the body-facing surface of the absorbent article as a whole, and the clothing-facing surface of the outer cover nonwoven material forms at least a portion of the clothing-facing surface of the absorbent article as a whole.
[0070] As used herein, "wearer's skin" refers to those parts of the skin that are covered by the absorbent article. In the following test methods, collagen is used to represent the wearer's skin.
[0071] The absorbent article comprises a polyol and a urease inhibitor.
[0072] Skin health and protection from biological insults are very important to the wearer of the absorbent article 10. Absorbent articles 10 such as diapers, pants, adult incontinence products are worn so that they are in direct contact with the wearer's skin. An inevitable consequence of using absorbent articles 10 is that the skin is more directly exposed to various physical and biological insults. Therefore, the barrier function of the skin covered by the absorbent article 10 is at risk.
[0073] The decomposition of urea that has entered an absorbent article 10, such as a diaper or pants, results in the formation of ammonia. The decomposition of urea is catalyzed by urease, which is produced by bacteria present in the skin and feces. Therefore, inhibiting urease activity inside the absorbent article 10 can help reduce the extent of ammonia formation. It has been found that ammonia increases skin pH.
[0074] The pH of the skin should be between 4.5 and 6, or optimally between 4.7 and 5.75. Therefore, the natural pH of the skin is slightly acidic. This mildly acidic pH is produced by the skin's acid mantle, which is the water portion of the hydrolipidic film that protects the outer layer of the skin.
[0075] The pH of the skin has been found to play an important role in the condition of the skin. The acid mantle is key to the skin's protective barrier. For example, it inhibits the growth of bacteria and restores and maintains the optimal acidic environment in which the skin's natural flora can thrive. If the pH of the skin rises into the alkaline range, its natural balance is disturbed. The essential epidermal lipids cannot be synthesized, and the skin loses water and dries out. In this case, the outer layer of the skin (or epidermis) is no longer able to function as a protective barrier.
[0076] When the barrier function of the skin is impaired, it is less elastic and more sensitive to environmental triggers. It may become dry, sensitive or allergic, and if this occurs in the area of the skin covered by the absorbent article 10, so-called diaper rash may occur.
[0077] Therefore, it is highly desirable to maintain the pH of the skin in contact with the absorbent article 10 within the range of pH 4.5 to 6. Considering that elevated levels of ammonia have been found to help increase skin pH, one way to help maintain a slightly acidic skin pH is to maintain low ammonia levels inside the diaper. This, in turn, can be achieved by reducing the extent of urea decomposition within the absorbent article 10 during use, such as by providing a urease inhibitor.
[0078] The inventor has found that the absorbent article 10 comprising a polyol and a urease inhibitor is particularly beneficial for maintaining a low ammonia level inside a diaper. More specifically, the urease inhibitor can be provided as a solution and / or suspension with a polyol. The solution and / or suspension comprising the urease inhibitor and the polyol has a high viscosity. Nevertheless, the solution and / or suspension comprising the urease inhibitor and the polyol is soluble in water and urine. When dissolved, the urease inhibitor may be more easily transported to the place where urease is present in the urine in the absorbent article 10, thereby improving its efficiency. The immersed polyol is also transported to the place where urine is finally stored (usually in the absorbent core 30). Due to its high viscosity and thickness, respectively, the solution and / or suspension sticks to the part of the absorbent article 10 to which it is applied. Due to this viscosity, it can also withstand force, particularly mechanical force and vacuum force, and this part of the diaper is discarded during assembly on the production line. In contrast, when the urease inhibitor is applied to a part of the absorbent article 10 in its solid form, part of the powder can be removed due to mechanical force and / or vacuum force. Similarly, when applied with a solution in a solvent with a low boiling point such as water or a monohydric alcohol, the solvent can be removed due to the vacuum applied during manufacture, and the remaining urease inhibitor powder can be removed due to mechanical force and / or vacuum force. In addition, the solution can penetrate into the part of the absorbent article and / or interact with the part of the absorbent article, and the solution is not applied to the part of the absorbent article due to the hygroscopic force in the absorbent article 10. Therefore, due to the high viscosity of the solution and / or suspension containing the urease inhibitor and the polyol, the urease inhibitor can be more effectively applied to a specific position and / or part of the absorbent article. In addition, applying a solution and / or suspension containing the urease inhibitor and the polyol is conducive to dosing the urease inhibitor because no or only a small amount of the solution and / or suspension is removed during manufacture. In addition, the concentration distribution of the urease inhibitor in the absorbent article 10 can be more easily achieved.
[0079] Furthermore, it has been discovered that the urease inhibitor need not be applied so that it is close to and can be transferred to the wearer's skin, such as by incorporating the urease inhibitor into a body lotion applied to the body-facing surface of the topsheet 26, or by otherwise disposing the urease inhibitor on the body-facing surface of the topsheet 26. In one aspect, it has been discovered that the urease inhibitor and the polyol can be included beneath the topsheet 26, i.e., between the second body-facing surface of the topsheet 26 and the absorbent core 30 and / or within the absorbent core 30.
[0080] Although urine and feces initially contact the body-facing surface of the top sheet 26, it has been found that it is not necessary to place the urease inhibitor on the wearer-facing surface of the top sheet 26 to be able to soak into the urine. Instead, it has been found that it is beneficial to place the urease inhibitor deeper inside the absorbent article 10 and therefore below the top sheet 26, positioning the urease inhibitor in or near the location where urine is ultimately stored (usually within the absorbent core 30). In particular, during the manufacture of the absorbent article 10, a suspension and / or solution containing a urease inhibitor and a polyol is applied to and thus placed in a layer or on a surface that participates in fluid transfer between the top sheet 26 and the absorbent core 30, promoting the dissolution of the urease inhibitor in urine and thus enhancing the activity of the urease inhibitor.
[0081] Furthermore, positioning the urease inhibitor away from the skin contacting surface of the absorbent article 10 eliminates or greatly reduces the amount of urease inhibitor that comes into direct contact with the wearer's skin. While suitable urease inhibitors are not harmful to the skin, reducing the number of different substances and compounds that are transferred to the skin may be appreciated by the user, since exposing the skin to a variety of different substances may be stressful to the skin. In particular, for soluble urease inhibitors, it is desirable to avoid skin contact to prevent transfer to deeper skin areas - again, although without exposing the wearer to any known risks.
[0082] The absorbent article 10 comprising a urease inhibitor and a polyol, and in particular the absorbent article 10 comprising a soluble natural urease inhibitor, thus beneficially helps to improve the skin health of the wearer and thereby avoid diaper rash.
[0083] The absorbent article 10 of the present invention comprises a liquid permeable topsheet 26, a liquid impermeable backsheet 28, an absorbent core 30, and optionally at least one acquisition and distribution layer 38. The absorbent core 30 is disposed between the topsheet 26 and the backsheet 28; and optionally at least one acquisition and distribution layer 38 is disposed between the topsheet 26 and the absorbent core 30. The absorbent article 10 comprises a polyol and a urease inhibitor.
[0084] The liquid-permeable topsheet 26 has a first surface and a second surface opposite the first surface, which correspond to the body-facing surface and the garment-facing surface in the assembled absorbent article 10. The body-facing (i.e., second) surface can be in direct contact with the skin of the wearer of the absorbent article 10.
[0085] The absorbent core 30 has a first surface and a second surface opposite the first surface, which correspond to the body-facing (i.e., first) surface and the garment-facing (i.e., second) surface in the assembled absorbent article 10. In the assembled absorbent article 10, the garment-facing second surface of the absorbent core 30 may be in direct contact with the backsheet 28. It is known that under anaerobic conditions, certain bacteria use a denitrification process to produce energy. Specifically, they use nitrates (e.g., derived from ammonia) to oxidize glucose as their metabolic pathway for energy generation. Therefore, it has been found that in order to reduce ammonia production in the absorbent article 10 during use, in addition to the use of urease inhibitors, an absorbent structure having a high permeability to promote aerobic conditions inside the absorbent article 10 can be beneficial. In one aspect of the present invention, the absorbent core 30 provided therefore has 10 -6 cm 2 Up to 10 -4 cm 2 Good permeability can be achieved, for example, by providing the absorbent core 30 with areas of reduced thickness, such as elongated "channels" within the absorbent core 30, in which little or no absorbent material is provided.
[0086] The urease inhibitor and the polyol may be included in the absorbent core 30. In particular, the suspension and / or solution containing the urease inhibitor and the polyol may be applied to the first surface and / or the second surface of the absorbent core 30. In particular, it may be applied to the first surface of the absorbent core 30. This step may be performed before the absorbent core is provided on the production line or during the assembly of the absorbent article 10 on the production line. The urease inhibitor and the polyol may be included in the absorbent core 30. In the absorbent core, the suspension and / or solution containing the urease inhibitor and the polyol may be applied illustratively to the SAP material, the SAP particles, respectively.
[0087] The optional at least one acquisition and distribution layer (ADL) 38 has a first surface and a second surface opposite the first surface, which correspond to the body-facing surface and the garment-facing surface in the assembled absorbent article 10. Preferably, at least one ADL 38 is provided. The optional at least one ADL 38 may include or consist of a first layer and a second layer. The optional ADL 38 and any of its layers cannot be longer than the absorbent core 30 along the longitudinal dimension of the absorbent article 10. In addition, the optional ADL 38 and any of its layers cannot be wider than the absorbent core 30 along the transverse dimension of the absorbent article 10.
[0088] Urease inhibitors and polyols may be included in the optional at least one ADL 38. In a specific example, at least one ADL 38 may be included in the absorbent article 10, and the urease inhibitor and polyol may be included in the at least one ADL 38. Due to the properties and functions of the ADL 38, the absorption of the urease inhibitor in the urine collected and distributed by the ADL 38 is increased before the urine reaches the absorbent core 30 and is absorbed by the SAP material, SAP particles, respectively. At least the ADL 38 may include part, preferably most or even the total amount of the urease inhibitor and / or polyol contained in the absorbent article 10. In particular, the at least one ADL 38 may include part, preferably most or even the total amount of the suspension and / or solution containing the urease inhibitor and polyol included in the absorbent article 10. The suspension and / or solution can be applied to the optional at least one ADL 38 by applying the suspension and / or solution containing the urease inhibitor and polyol to the first surface and / or second surface of the optional at least one ADL 38. The suspension and / or solution may also be included in the optional at least one ADL 38. The ADL 38 may include at least a first layer and a second layer. It may include a fiber web and / or a thread disposed between the first layer and the second layer. The fiber web and / or the thread may contain a urease inhibitor and a polyol, or a suspension and / or a solution containing a urease inhibitor and a polyol. A portion, preferably a majority or even the total amount of the suspension and / or the solution containing a urease inhibitor and a polyol included in the absorbent article 10 may be included in the fiber web and / or the thread. In the optional at least one ADL 38, the suspension and / or the solution containing the urease inhibitor may be applied illustratively to the surface of the first layer included in the ADL 38, which is in direct contact with the second layer included in the ADL 38. The urease inhibitor and therefore also the suspension and / or the solution containing the polyol and the urease inhibitor are generally not colorless, and therefore may be confused with contaminants when visible in the assembled absorbent article. Therefore, it may be desirable that the surface of the ADL 38 that faces the absorbent core 30, or a layer within the ADL 38 that is adjacent to the absorbent core 30, contain a urease inhibitor and a polyol or a suspension and / or solution of a urease inhibitor and a polyol.
[0089] In one aspect, the present invention relates to a method for making an absorbent article 10, the method comprising the steps of
[0090] a) suspending and / or dissolving a urease inhibitor in a polyol to form a suspension and / or solution comprising the urease inhibitor and the polyol;
[0091] b) applying the suspension and / or solution to one or more of the following:
[0092] - a liquid-permeable top sheet 26,
[0093] - an absorbent core 30, and
[0094] - at least one acquisition and distribution layer 38;
[0095] c) assembling the absorbent article 10 such that the absorbent core 30 is disposed between the topsheet 26 and the backsheet 28 ; and the at least one optional acquisition and distribution layer 38 is disposed between the topsheet 26 and the absorbent core 30 .
[0096] As previously mentioned, urease inhibitors and polyols may be included in the optional at least one ADL 38. Thus, in this method, a suspension and / or solution is applied to at least one acquisition and distribution layer 38.
[0097] During assembly of the absorbent article 10, a suspension and / or solution containing a urease inhibitor and a polyol may be applied to a web and / or threads disposed between the absorbent core 30 and at least one acquisition and distribution layer 38 or as part of at least one acquisition and distribution layer 38. In particular, the at least one acquisition and distribution layer 38 may include at least a first layer and a second layer; and the web and / or threads may be disposed between the first layer and the second layer. Due to this configuration and method steps, the suspension and / or solution containing a urease inhibitor and a polyol may be applied to the web and / or threads outside the production line, and modifications to production may be minimized. Thus, it is not necessary to introduce a device for handling the suspension and / or solution into the line. In one example, a suspension and / or solution containing a urease inhibitor and a polyol may be applied to the web. A portion, preferably a majority or even the total amount of the suspension and / or solution containing a urease inhibitor and a polyol contained in the absorbent article 10 may be applied to the web. The web may include natural fibers or modified natural fibers, in particular viscose fibers or cotton fibers. In one example, a suspension and / or solution comprising a urease inhibitor and a polyol can be applied to the threads. The threads can include natural fibers or modified natural fibers, in particular viscose fibers or cotton fibers. A portion, preferably a majority or even the total amount of the suspension and / or solution comprising a urease inhibitor and a polyol included in the absorbent article 10 can be applied to the threads.
[0098] The urease inhibitor and the polyol, or a suspension and / or a solution comprising the urease inhibitor and the polyol, may be applied to at least one surface selected from the group consisting of: the first surface of the top sheet 26, the first surface of the absorbent core 30, the first surface and the second surface of the optional at least one ADL 38. Alternatively, the urease inhibitor and the polyol, or a suspension and / or a solution comprising the urease inhibitor and the polyol, may be applied within the optional at least one ADL 38. Alternatively, the urease inhibitor and the polyol, or a suspension and / or a solution comprising the urease inhibitor and the polyol, may be included within the absorbent core 30. In further alternatives, the urease inhibitor and the polyol, or a suspension and / or a solution comprising the urease inhibitor and the polyol, may be applied to at least one portion selected from the group consisting of: the first surface of the top sheet 26, the first surface of the absorbent core 30, the first surface and the second surface of the optional at least one ADL 38, and within the optional ADL. Alternatively, the urease inhibitor and the polyol, or the suspension and / or solution containing the urease inhibitor and the polyol, may be applied to at least one portion selected from the group consisting of: the first surface of the top sheet 26, the first surface of the absorbent core 30, the first and second surfaces of the optional at least one ADL 38, and the inside of the absorbent core 30. In addition, the urease inhibitor and the polyol, or the suspension and / or solution containing the urease inhibitor and the polyol, may be applied to at least one portion selected from the group consisting of: the first surface of the top sheet 26, the first surface of the absorbent core 30, the first and second surfaces of the optional at least one ADL 38, the inside of the optional ADL, and the inside of the absorbent core. In another alternative, the urease inhibitor and the polyol, or the suspension and / or solution containing the urease inhibitor and the polyol are included in the optional ADL and in the absorbent core 30. Therefore, in the absorbent article 10, the urease inhibitor and the polyol, or the suspension and / or solution containing the urease inhibitor and the polyol are included between the second surface of the top sheet 26 and the absorbent core 30 and / or are present in the absorbent core 30. Thus, the urease inhibitor is not disposed on the body-facing surface of the absorbent article 10 (which is the second, body-facing surface of the topsheet 26).
[0099] Urease inhibitors and polyols, or suspensions and / or solutions containing urease inhibitors and polyols can be applied to natural fibers or modified natural fibers, in particular, viscose fibers or cotton fibers included in the first surface of the top sheet 26, optionally at least one ADL 38, or the absorbent core 30. Suspensions and / or solutions containing urease inhibitors and polyols adhere more closely to natural fibers and modified natural fibers due to texture, in particular the surface texture of such fibers. Therefore, during the manufacturing process, when the absorbent article or a portion thereof is exposed to external forces (such as due to suction by a vacuum device), the suspensions and / or solutions containing urease inhibitors and polyols are not removed from the first surface of the top sheet 26, optionally at least one acquisition and distribution layer 38, or the absorbent core 30, or at least are removed to a reduced amount than when applied to other fibers. In particular, suspensions and / or solutions containing urease inhibitors and polyols can be applied to natural fibers or modified natural fibers included in at least one ADL 38. The ADL 38 can include a layer comprising, consisting essentially of, or consisting of natural fibers or modified natural fibers to which a suspension and / or solution containing a urease inhibitor and a polyol can be applied. In particular, the layer can be disposed in direct contact with the absorbent core 30 in the absorbent article 10.
[0100] Although it is known to apply urease inhibitors such as green tea on the top sheet 26 of the absorbent article 10, for example, when green tea extract is applied to the top sheet 26 in the form of a body lotion, the amount of these compounds in the body lotion is generally very low. Such a low amount may not be sufficient to obtain the desired result, i.e., to keep the skin pH within the desired range. When incorporated into, for example, a body lotion, it may become challenging to use a urease inhibitor to keep the pH of the wearer's skin within the desired range in the amount of urease inhibitor in the urine required. In addition, the body lotion provided on the top sheet 26 of the absorbent article 10 is generally hydrophobic and contains very little or no water. Therefore, the urease inhibitor can be "trapped" in the body lotion, which can limit its ability to reduce the decomposition of urea by urease. Therefore, a higher amount of urease inhibitor may also be insufficient to keep the pH of the wearer's skin within the desired range. Applying the urease inhibitor beneath the topsheet 26 and additionally in a form that maximizes its solubility in urine (particularly in the form of a suspension and / or solution with a polyol) makes it easier to increase the amount of urease inhibitor to a level that can actually help maintain skin pH within the desired range.
[0101] The urease inhibitor may be a natural urease inhibitor. Urease inhibitors and natural urease inhibitors are described in more detail below.
[0102] As discussed above, urease inhibitors should not be present on the body-facing surface of the absorbent article 10 (which is the second body-facing surface of the top sheet 26) to avoid any potential absorption through the wearer's skin. Due to its solubility, the solubility of the polyol, and the nature of the fluid transport channel in the absorbent article 10, the urease inhibitor can be carried in urine from the layer including it and / or the absorbent core 30 to the location where the urine is finally stored (usually in the absorbent core 30). In particular, it should be prevented from reaching the second body-facing surface of the top sheet 26, the skin of the wearer, respectively. Although it is less preferred due to the reduced distance to the wearer's skin, it is included between the second surface top sheet 26 and the absorbent core 30 to provide a urease inhibitor and a polyol applied to the first surface of the top sheet 26, or a suspension and / or solution containing the urease inhibitor and the polyol, which first surface is the surface of the top sheet 26 facing clothes in the assembled absorbent article 10. Preferably, the urease inhibitor and the polyol, or the suspension and / or solution containing the urease inhibitor and the polyol, can be applied to at least one surface selected from the group consisting of: the first surface of the absorbent core 30, the first surface and the second surface of the optional at least one ADL 38, and / or the inside of the optional at least one ADL 38 and / or the inside of the absorbent core 30. In a specific example, at least one ADL 38 can be included in the absorbent article 10, and the urease inhibitor and the polyol, or the suspension and / or solution containing the urease inhibitor and the polyol, are applied to the first surface and / or the second surface and / or therein of at least one ADL 38. Due to the properties and functions of the ADL 38, the absorption of the urease inhibitor in the urine collected and distributed by the ADL 38 is increased before the urine reaches the absorbent core 30 and is absorbed by the SAP material, SAP particles, respectively. A similar effect is achieved when the solution is applied to the first surface of the absorbent core 30. Furthermore, in some examples, in addition to being applied to at least one surface selected from the group consisting of: the first surface of the top sheet 26, the first surface of the absorbent core 30, the first and second surfaces of optionally at least one ADL 38, and / or within optionally at least one ADL 38, the solution can also be applied within the absorbent core 30.
[0103] In the assembled absorbent article 10, an absorbent core 30 is provided that includes a first surface area facing the top sheet 26 (also the body-facing surface of the absorbent core 30). The body-facing surface of the absorbent core 30 has a certain surface area (which can be easily determined using a ruler). Based on the total body-facing surface area of the absorbent core 30, the urease inhibitor can be at least 3 g / m 2 , or at least 5g / m 2 , or at least 8g / m 2 , or at least 10g / m 2 , or at least 12g / m 2Based on the total body-facing surface area of the absorbent core 30, the urease inhibitor may not exceed 200 g / m 2 , or not more than 150g / m 2 , or not more than 120g / m 2 , or not more than 100g / m 2 , or not more than 80g / m 2 For absorbent articles 10 in which the urease inhibitor is not uniformly distributed, these amounts of the urease inhibitor are average amounts based on the total body-facing surface area of the absorbent core 30. The fact that these amounts are related to the body-facing surface area of the absorbent core 30 does not mean that the urease inhibitor actually needs to be disposed on the surface area of the absorbent core 30. Instead, the urease inhibitor or a suspension and / or solution comprising the urease inhibitor and the polyol can be included in a number of different locations as described and specified herein.
[0104] The assembled absorbent article 10 has a longitudinal centerline 50 and a longitudinal dimension extending along the longitudinal centerline 50, and a transverse centerline 48 perpendicular to the longitudinal centerline 50. The absorbent article 10 may include a front waist region 12 having a front waist edge 18, a back waist region 16 having a back waist edge 20, and a crotch region 14 extending longitudinally between the front waist region and the back waist region 16. The absorbent article 10 may have a longitudinal dimension extending from the front waist edge 18 to the back waist edge 20 along the longitudinal centerline 50. The front waist region 12, the back waist region 16, and the crotch region 14 may each form one-third of the longitudinal dimension of the absorbent article 10.
[0105] The amount of urease inhibitor in the crotch region 14 may be higher than that in the back waist region 16. The amount of urease inhibitor in the crotch region 14 may be at least 10% by weight, or at least 20% by weight, or at least 50% by weight, or at least 100% by weight higher than that in the back waist region 16. The amount of urease inhibitor in the crotch region 14 may be no more than 300% by weight higher than that in the back waist region 16.
[0106] The amount of urease inhibitor in the front waist region 12 may be higher than that in the back waist region 16. The amount of urease inhibitor in the front waist region 12 may be at least 10% by weight, or at least 20% by weight, or at least 50% by weight, or at least 100% by weight higher than that in the back waist region 16. The amount of urease inhibitor in the front waist region 12 may be no more than 250% by weight higher than that in the back waist region 16.
[0107] The amount of urease inhibitor in the crotch region 14 may be higher than that in the front waist region 12. The amount of urease inhibitor in the crotch region 14 may be at least 3% by weight, or at least 5% by weight, or at least 8% by weight higher than that in the front waist region 12. The amount of urease inhibitor in the crotch region 14 may be no more than 25% by weight, or no more than 20% by weight higher than that in the front waist region 12.
[0108] The absorbent core 30 in the assembled absorbent article 10 may include a front region having a front edge, a back region having a back edge, and a crotch core region extending longitudinally between the front region and the back region of the absorbent core 30. The front region, the back region, and the crotch core region may each form one third of the longitudinal dimension of the absorbent core 30.
[0109] If the urease inhibitor is applied in the absorbent core 30 and / or ADL 38 and / or on any of the corresponding surfaces, and is therefore contained by the absorbent core 30 or by the optional ADL 38 in the assembled absorbent article 10, the amount of the urease inhibitor may be higher in the crotch core region of the absorbent core 30 than in the back region. The amount of the urease inhibitor in the crotch core region may be at least 10% by weight, or at least 20% by weight, or at least 50% by weight, or at least 100% by weight higher than the amount in the back region. The amount of the urease inhibitor in the crotch core region may be no more than 300% by weight higher than the amount in the back region.
[0110] If the urease inhibitor and the polyol, or a suspension and / or solution containing the urease inhibitor and the polyol, are included by the absorbent core 30 or by the ADL 38 (see below), the amount of the urease inhibitor in the front region of the absorbent core 30 may be higher than that in the back region. The amount of the urease inhibitor in the front region may be at least 10% by weight, or at least 20% by weight, or at least 50% by weight, or at least 100% by weight higher than that in the back region. The amount of the urease inhibitor in the front region may be no more than 15% by weight, or no more than 10% by weight higher than that in the back region.
[0111] If the urease inhibitor and the polyol, or a suspension and / or solution containing the urease inhibitor and the polyol, are included by the absorbent core 30 or by the ADL 38 (see below), the amount of the urease inhibitor in the crotch core region of the absorbent core 30 may be higher than in the front region. The amount of the urease inhibitor in the crotch core region may be at least 3% by weight, or at least 5% by weight, or at least 8% by weight, or at least 10% by weight higher than in the front region. The amount of the urease inhibitor in the crotch core region may be no more than 25% by weight, or no more than 20% by weight higher than in the front region.
[0112] By using a urease inhibitor having a non-uniform distribution in the longitudinal dimension as described in the previous paragraph, a higher amount of urease inhibitor is provided in those areas of the absorbent article 10 that are exposed to and store a large amount of urine, namely the crotch region 14 (and the crotch core region), and a slightly smaller degree of urease inhibitor is provided in the front waist region 12 and the front region of the absorbent core 30. Therefore, urine is easily exposed to the urease inhibitor provided in the absorbent article 10. At the same time, a smaller amount of urease inhibitor can be applied in some areas, particularly in the back waist region 16 and the back waist region of the absorbent core 30, thereby reducing the overall use of urease inhibitor in the absorbent article 10, while still achieving the goal of maintaining the skin pH within the desired range. This makes it possible to reduce the cost of the urease inhibitor and avoid excessive amounts of urease inhibitor, considering that although these compounds are beneficial, they should not be applied without a reasonable purpose.
[0113] A non-uniform distribution as described above can be obtained, for example, by applying the urease inhibitor and the polyol, or a suspension and / or solution comprising the urease inhibitor and the polyol, to a compound such as SAP particles or airfelt (pulp) of the absorbent core 30, and / or by applying the urease inhibitor and the polyol, or a suspension and / or solution comprising the urease inhibitor and the polyol, to a compound of one or more layers of the optional ADL 38. These compounds are generally non-uniformly distributed in the longitudinal dimension of the absorbent core 30 and the absorbent article 10. Instead, a higher amount is provided in the crotch region 14 and the crotch core region, a slightly smaller amount is provided in the front waist region 12 and the front region of the absorbent core 30, and an even smaller amount is provided in the rear waist region 16 and the rear region of the absorbent core 30. Thus, by not applying the suspension and / or solution comprising the urease inhibitor and the polyol directly into the absorbent article 10 / absorbent core 30, but applying it indirectly via compounds applied to the absorbent core 30 and / or ADL 38 and subsequently disposing these compounds in the absorbent article 10, the desired non-uniform distribution can be readily obtained. Furthermore, given that the absolute amount of urease inhibitor will typically be quite small, incorporating the urease inhibitor into the absorbent article 10 via other compounds enables reliable provision of the urease inhibitor. Although it may be challenging to obtain the desired distribution in a reliable manner when applying the suspension and / or solution comprising the urease inhibitor and the polyol directly in a very fast-running absorbent article 10 production line, such application is still convenient compared to applying the urease inhibitor in solid form (e.g., as a powder).
[0114] The weight ratio of the total amount of polyol to the total amount of urease inhibitor may be from 10: 1 to 1:4, preferably from 5: 1 to 1:3, more preferably from 2: 1 to 1:2 or even 1: 1. In particular, the suspension and / or solution comprising or consisting of the polyol and the urease inhibitor has a weight ratio of 10: 1 to 1:4, preferably 5: 1 to 1:3, more preferably 2: 1 to 1:2 or even 1: 1. Such a ratio ensures that the amount of urease inhibitor absorbed by urine during use of the absorbent article 10 remains high enough to be effective, while the suspension and / or solution comprising the polyol and the urease inhibitor remains viscous enough to remain on or in the portion of the absorbent article 10 in which it is included, even when exposed to different forces on the production line.
[0115] Polyols
[0116] Polyols and their corresponding properties are known in the art. According to the present invention, the polyol is preferably miscible with water. In particular, it is soluble in water. In addition, it is soluble in urine. In this context, soluble in urine means that it exhibits a sufficiently high solubility to completely dissolve in the large amount of urine to which it is exposed during diaper use. Exemplarily, the total amount of polyol contained in the absorbent article 10 is soluble in 300 ml of urine, which corresponds to the standard maximum capacity of children's diapers. Thereby, it is ensured that the urease inhibitor is also soluble in urine, and therefore the beneficial effects discussed previously can be achieved.
[0117] The polyol should be selected to be non-toxic. Thus, if the diaper is used in an unintentional manner and the wearer is exposed to the polyol, potential hazards can be minimized. In particular, the polyol does not have to be labeled according to the Globally Harmonized System of Classification and Labelling of Chemicals. In particular, it may be preferred to select a polyol that is approved by the FDA for use in food, pharmaceutical preparations or for use in medical treatments. The polyol may have a boiling point of at least 100° C., preferably at least 150° C., more preferably at least 200° C. or even at least 250° C. at atmospheric pressure.
[0118] The polyol may be a diol or triol having 2 to 5 carbon atoms. Thus, a beneficial viscosity and water solubility may be obtained. In a preferred example, the polyol may be glycerol. Glycerol exhibits all of the desired properties described above. In addition, it is colorless and odorless. In addition, it advantageously exhibits antimicrobial and antiviral properties.
[0119] Urease inhibitors
[0120] Urease inhibitors are well known in the art. They can be chemically synthesized or derived from natural sources. Some known urease inhibitors are toxic. For use in the present invention, urease inhibitors should not be toxic when used close to the wearer's skin.
[0121] Urease inhibitors include transition metal ions and soluble salts thereof, such as silver salts, copper salts, zinc salts, iron salts and aluminum salts. Anions may also provide urease inhibition, such as borates, phytates, etc. Potentially valuable compounds include, but are not limited to, silver chlorate, silver nitrate, mercuric acetate, mercuric chloride, mercuric nitrate, copper metaborate, copper bromate, copper bromide, copper chloride, copper dichromate, copper nitrate, copper salicylate, copper sulfate, zinc acetate, zinc borate, zinc phytate, zinc bromate, zinc bromide, zinc chlorate, zinc chloride, zinc sulfate, cadmium acetate, cadmium borate, cadmium bromide, cadmium chlorate, cadmium chloride, cadmium formate, cadmium iodate, cadmium iodide, cadmium permanganate, cadmium nitrate, cadmium sulfate and gold chloride.
[0122] Other salts disclosed to have urease inhibiting properties include iron and aluminum salts, especially nitrates and bismuth salts. Other urease inhibitors include hydroxamic acid and its derivatives; thiourea; hydroxylamine; salts of phytic acid; phenyl diaminophosphorodiamidates / diaminophenylphosphorodiamidates; metal aryl phosphoramidate complexes, including substituted diaminophosphorodiamidate compounds; phosphoramidates without substitution on nitrogen.
[0123] For the present invention, natural urease inhibitors are preferred. As used herein, "natural urease inhibitors" are derived from natural sources. Natural urease inhibitors can be plant-based, that is, the urease inhibitor can be a plant with urease inhibitory activity, or can be an extract obtained from such a plant.
[0124] The natural urease inhibitor used in the present invention can be green tea (Camellia sinensis), grape seed, red grape seed extract, aloe vera, witch hazel (Hamamelis virginiana), German chamomile (Chamomilla recutita), calendula officinalis, sage (Salviaofficinalis), yucca (Yucca schidigera), and combinations and mixtures thereof.
[0125] Other useful urease inhibitors isolated and identified from plants are terpenoids, phenolic compounds, alkaloids, and combinations and mixtures thereof, as well as combinations and mixtures with the urease inhibitors described in the preceding paragraphs.
[0126] Preferred urease inhibitors of the present invention are green tea (Camellia sinensis), grape seed extract, and epigallocatechin gallate (EGCG), and combinations and mixtures thereof.
[0127] EGCG is an ester of epigallocatechin and gallic acid, a type of catechin. It is found in high concentrations in the dry leaves of green tea (about 7380 mg / 100 g), white tea (about 4245 mg / 100 g), and to a lesser extent black tea (about 936 mg / 100 g). Therefore, for the present invention, it is considered an extract of (green) tea.
[0128] Surprisingly, the inventors have also found that for natural urease inhibitors, particularly green tea extracts, the activity of urease inhibitors can be improved by bringing them into solution and removing all or most of the insoluble parts before applying them to the part of the absorbent article 10. Without being bound by theory, the presence of different soluble catechins seems to provide a synergistic effect that increases the activity of urease inhibitors. Although it is generally known that EGCG, such as from green tea extract, is one of the most effective urease inhibitors, the inventors have found that EGCG is less effective in its pure form (>92 wt %) than when applied with one or more other catechins, and it is believed that the urease inhibitory activity of the other catechins is lower than the urease inhibitory activity of EGCG. Therefore, the solution applied during the method of the present invention can include a urease inhibitor, which includes more than 50 wt %, particularly more than 80 wt % or even more than 90 wt % of EGCG. It may be desirable that the urease inhibitor includes at least one catechin different from EGCG, particularly the urease inhibitor includes more than 3 wt %, more than 5 wt % or even more than 10 wt % of one or more catechins different from EGCG. In particular, the urease inhibitor can be selected to contain EGCG, illustratively more than 50 wt%, more than 80 wt%, or even more than 90 wt% EGCG, and more than 3 wt%, more than 5 wt%, or even more than 10 wt% of a catechin other than EGCG, before dissolving it in a solvent and removing any insoluble portion.
[0129] Therefore, the present invention may also relate to an absorbent article 10, wherein the urease inhibitor comprises greater than 50 wt%, greater than 80 wt%, or even greater than 90 wt% EGCG. It may be desirable that the urease inhibitor also comprises catechins other than EGCG, in particular the urease inhibitor comprises more than 3 wt%, more than 5 wt%, or even more than 10 wt% catechins other than EGCG.
[0130] In particular, the urease inhibitor may be a green tea extract.
[0131] Illustratively, the absorbent article 10 comprises a natural urease inhibitor selected from the group consisting of green tea, an extract from green tea, grape seed, an extract from grape seed, and combinations thereof.
[0132] The urease inhibitor may be disposed on at least one surface selected from the group consisting of the first surface of the top sheet 26, the first surface of the absorbent core 30, the first surface and the second surface of at least one ADL 38, and / or disposed within at least one ADL 38 and / or within the absorbent core 30.
[0133] The urease inhibitor may be disposed on and / or within at least one ADL 38 in the absorbent article 10 .
[0134] The absorbent core 30 has a first body-facing surface having a surface area and wherein the urease inhibitor can be present at 3 g / m 2 based on the total body-facing surface area of the absorbent core 30. 2 Up to 200g / m 2 , or 5g / m 2 Up to 100g / m 2 amount applied.
[0135] The absorbent article 10 may have a longitudinal centerline 50 and a longitudinal dimension extending along the longitudinal centerline 50, and a transverse centerline 48 perpendicular to the longitudinal centerline 50, and include a front waist region 12 having a front waist edge 18, a back waist region 16 having a back waist edge 20, and a crotch region 14 extending longitudinally between the front waist region and the back waist region 16; having a longitudinal dimension extending from the front waist edge 18 to the back waist edge 20 along the longitudinal centerline 50, each region forming one third of the longitudinal dimension, and wherein a solution of a urease inhibitor may be applied so that the amount of urease inhibitor in the crotch region 14 is higher than the amount in the back waist region 16.
[0136] The amount of urease inhibitor in the front waist region 12 of the absorbent article 10 may be higher than that in the back waist region 16. In addition, the amount of urease inhibitor in the crotch region 14 may be higher than that in the front waist region 12.
[0137] In one aspect, the present invention may also be directed to an absorbent article 10 comprising a polyol and a urease inhibitor, wherein the urease inhibitor is used to maintain the pH of the wearer's skin within the range of 4.0 to 6.0 according to the Urease Activity Test Method described herein. Although the Urease Activity Test Method is not performed on the wearer and therefore does not include any steps of contacting the absorbent article 10 with the wearer's skin, the Urease Activity Test Method has been carefully set to "simulate" as closely as possible the conditions that typically occur during use of the absorbent article 10. In fact, the Urease Activity Test Method is believed to provide a more objective measurement because it excludes various potential other factors that may affect the pH of the wearer's skin.
[0138] In absorbent articles 10 comprising a polyol and a urease inhibitor, the urease inhibitor may also be used to maintain the pH of the topsheet 26 within the range of 5.0 to 7.5, or within the range of 5.0 to 7.0, according to the test method described herein.
[0139] Urease inhibitors may also be used to maintain the amount of ammonia below 10 ppm, or below 8 ppm, or below 5 ppm according to the urease activity test method described herein.
[0140] During use of an absorbent article 10 comprising a polyol and a urease inhibitor, a portion of the urine that has been transferred through the topsheet 26 into the absorbent article 10 may penetrate back through the topsheet 26 before it can be absorbed and stored by the absorbent core 30. This is also referred to as "rewetting". However, if the urine inhibitor is applied below the topsheet 26, at least a portion of the inhibitor may be "washed out" of the absorbent article 10 by dissolving in urine, which then penetrates back through the topsheet 26 onto the body-facing surface of the absorbent article 10. In order to reduce the amount of urease inhibitor that may be delivered to the wearer-facing surface of the absorbent article 10 during use, it is desirable that the absorbent article 10 have good rewetting properties. Therefore, according to the Post-Acquisition Collagen Rewetting Test Method described herein, the absorbent article 10 may have a Rewetting Amount of less than 150 mg, or less than 120 mg.
[0141] Absorbent products
[0142] The following disclosure of absorbent articles herein is intended to relate to aspects of the present invention (which relate to the absorbent articles themselves) and methods of making absorbent articles, i.e., the present disclosure is intended to describe aspects of the corresponding absorbent articles. Although urease inhibitors are not specifically described in the following disclosure of absorbent articles, and urease inhibitors are not shown in the accompanying drawings, it is self-evident that the absorbent articles of the present invention describe urease inhibitors as described and claimed herein and in the following examples.
[0143] An exemplary absorbent article 10 according to the present disclosure is shown in the form of a diaper (applied to a wearer with a belt) Figures 1 to 3 Shown in. Figure 1 To illustrate a plan view of an absorbent article 10, the garment-facing surface 2 faces the viewer in a flat, flat condition (ie, without elastic contraction). Figure 2 for Figure 1 0048] Figure 1 is a plan view of an exemplary absorbent article 10 with the body-facing surface 4 facing the viewer in a flat, unfolded state. Figure 3 In the fastened configuration Figure 1 and Figure 2 10 is a front perspective view of an absorbent article 10. Figures 1 to 3 The absorbent article 10 is shown for illustrative purposes only, as the present disclosure can be used to make a variety of diapers, including, for example, adult incontinence products, pants, or other absorbent articles such as, for example, sanitary napkins and absorbent pads.
[0144] The absorbent article 10 may include a front waist region 12, a crotch region 14, and a back waist region 16. The crotch region 14 may extend intermediate the front waist region 12 and the back waist region 16. The front waist region 12, the crotch region 14, and the back waist region 16 may each be 1 / 3 of the length of the absorbent article 10. The absorbent article 10 may include a front waist edge 18, a back waist edge 20 opposite the front waist edge 18. The absorbent article 10 also includes longitudinally extending, laterally opposite side edges 22 and 24 defined by the chassis 52.
[0145] The absorbent article 10 comprises a liquid permeable topsheet 26, a liquid impermeable backsheet 28 and an absorbent core 30 positioned between the topsheet 26 and the backsheet 28. Hereinafter, the terms "topsheet" and "backsheet" are used only to describe the liquid permeable topsheet and the liquid impermeable backsheet.
[0146] The absorbent article 10 may also include one or more pairs of barrier leg cuffs 32 with or without elastic members 33 , one or more pairs of leg elastic members 34 , and one or more elastic waistbands 36 .
[0147] The absorbent article may further include at least one acquisition and distribution layer (ADL) 38 disposed between the topsheet 26 and the absorbent core 30 .
[0148] An outer cover material 40, such as a nonwoven material, may cover the garment-facing side of the backsheet 28. The absorbent article 10 may include rear ears 42 located in the rear waist region 16. The rear ears 42 may include fasteners 46 and may extend from the rear waist region 16 of the absorbent article 10 and be attached (using fasteners 46) to a landing zone area or landing zone material 44 on the garment-facing portion of the front waist region 12 of the absorbent article 10. The absorbent article 10 may also have front ears 47 in the front waist region 12. The absorbent article 10 may have a transverse centerline 48 and a longitudinal centerline 50. The transverse centerline 48 extends perpendicular to the longitudinal centerline 50.
[0149] In other cases, the absorbent article may be in the form of a pant having permanent or refastenable side seams. Suitable refastenable seams are disclosed in U.S. Patent Application Publication No. 2014 / 0005020 and U.S. Patent No. 9,421,137. See Figures 4 to 8 , an exemplary absorbent article 10 is shown in the form of a pant. Figure 4 It is a front perspective view of the absorbent article 10. Figure 5 This is a back perspective view of the absorbent article 10. Figure 6 is a plan view of an absorbent article 10 lying flat with the garment-facing surface facing the viewer. Figure 4-Figure 8 The same as above Figure 1-3 The same reference numeral elements are the same elements (eg, absorbent core 30). Figure 7 Taken along line 7-7 Figure 6Example cross-sectional view of an absorbent article. Figure 8 Taken along line 8-8 Figure 6 Example cross-sectional view of an absorbent article. Figure 7 and Figure 8 Example forms of the front belt 54 and the back belt 56 are shown. The absorbent article 10 may have a front waist region 12, a crotch region 14, and a back waist region 16. Each of the regions 12, 14, and 16 may be 1 / 3 of the length of the absorbent article 10. The absorbent article 10 includes a top sheet 26, a back sheet 28, and an absorbent core 30 at least partially disposed between the top sheet 26 and the back sheet 28, and optionally at least one acquisition and distribution layer (ADL) 38 disposed between the top sheet 26 and the absorbent core, similar to the above description of the absorbent article 10. Figures 1 to 3 The absorbent article 10 may include a front belt 54 located in the front waist region 12 and a back belt 56 located in the back waist region 16. The central infrastructure 52 (including the top sheet 26, the back sheet, the absorbent core and the optional ADL) may be joined to the body-facing surface 4 of the front belt 54 and the back belt 56. The side edges 23 and 25 of the front belt 54 may be joined to the side edges 27 and 29 of the back belt 56, respectively, to form two side seams 58. The side seams 58 may be any suitable seams known to those skilled in the art, such as, for example, abutting seams or overlapping seams. When the side seams 58 are permanently formed or closed in a refastenable manner, the absorbent article 10 in the form of pants has two leg openings 60 and a waist opening periphery 62. The side seams 58 may be permanently joined using, for example, an adhesive or bonding portion, or may be closed in a refastenable manner using, for example, hook and loop fasteners.
[0150] In another form, the absorbent article can be an absorbent insert used with a reusable outer cover. The insert can be disposable or reusable. The reusable outer cover can include a woven fabric or other material and can be configured as pants or diapers. In the context of diapers, the reusable outer cover can include a fastening system for joining the front waist area of the reusable outer cover to the rear waist area. The fastening system can include, for example, snaps, buttons and / or hooks and loops. The insert can include a liquid-permeable top sheet, a liquid-impermeable back sheet, and an absorbent core at least partially positioned between the top sheet and the back sheet. At least one acquisition and distribution layer (ADL) 38 is disposed between the top sheet and the absorbent core. The insert can include one or more pairs of leg cuffs and may not contain ear pieces, side pieces and / or waistbands. In some cases, a nonwoven material can be positioned on the side of the back sheet facing the garment. The garment-facing surface of the insert can be attached to the body-facing surface of the reusable outer cover via an adhesive, hook-and-loop fastener or other bonding methods. An example insert and reusable outer cover system is disclosed in U.S. Pat. No. 9,011,402 issued to Roe et al. on April 21, 2015. The insert or reusable outer cover may include a biobased content value of, for example, about 10% to about 100%, about 25% to about 100%, about 40% to about 100%, about 50% to about 100%, about 75% to about 100%, or about 90% to about 100% as measured using ASTM D6866-10 Method B.
[0151] bring
[0152] See also Figure 7 and Figure 8 , the front belt 54 and the back belt 56 may include a front inner belt layer 66 and a back inner belt layer 67 and a front outer belt layer 64 and a back outer belt layer 65, which have an elastomeric material (e.g., a strand 68 or a film (which may be apertured)) at least partially disposed between the inner belt layer and the outer belt layer. The elastic element 68 or the film may be relaxed (including being cut) to reduce the elastic strain on the absorbent core 30, or alternatively be continuously distributed over the entire absorbent core 30. The elastic element 68 may have uniform or variable spacing between them in any portion of the belt. The elastic element 68 may also be pre-strained by the same amount or by different amounts. The front belt 54 and / or the back belt 56 may have one or more elastic element free zones 70, wherein the base structure 52 overlaps the front belt 54 and the back belt 56. In other cases, at least some of the elastic elements 68 may extend continuously over the base structure 52.
[0153] The front inner belt layer 66 and the rear inner belt layer 67 and the front outer belt layer 64 and the rear outer belt layer 65 can be joined using adhesives, heat bonds, pressure bonds or thermoplastic bonds. Various suitable belt layer constructions can be found in US Patent Publication No. 2013 / 0211363.
[0154] The front belt end edge 55 and the rear belt end edge 57 can extend longitudinally beyond the front chassis end edge 19 and the rear chassis end edge 21 (such as Figure 6 25 and 27 to 29) or they may be coterminal. The front and rear belt sides 23, 25, 27 and 29 may extend laterally beyond the chassis sides 22 and 24. The front belt 54 and rear belt 56 may be continuous (i.e., have at least one continuous layer) from belt side edge to belt side edge (e.g., the lateral distance from 23 to 25 and from 27 to 29). Alternatively, the front belt 54 and rear belt 56 may be discontinuous from belt side edge to belt side edge (e.g., the lateral distance from 23 to 25 and from 27 to 29) such that they are discrete.
[0155] As disclosed in U.S. Pat. No. 7,901,393, the longitudinal length (along the central longitudinal centerline 50) of the rear band 56 may be greater than the longitudinal length of the front band 54, and this may be particularly useful for increasing hip coverage when the rear band 56 has a greater longitudinal length than the front band 54 adjacent or proximate the side seam 58.
[0156] The front outer belt layer 64 and the rear outer belt layer 65 may be separated from each other so that the layers are discrete, or the layers may be continuous so that the layers extend continuously from the front belt end edge 55 to the rear belt end edge 57. The same is true for the front inner belt layer 66 and the rear inner belt layer 67 - that is, they may also be longitudinally discrete or continuous. Furthermore, the front outer belt layer 64 and the rear outer belt layer 65 may be longitudinally continuous, while the front inner belt layer 66 and the rear inner belt layer 67 are longitudinally discrete so that gaps are formed between them - the gaps between the front and rear inner and outer belt layers 64, 65, 66 and 67 are shown in FIG. Figure 7 and the gap between the front inner belt layer 66 and the rear inner belt layer 67 is shown in Figure 8 middle.
[0157] The front and back bands 54, 56 may include slits, holes and / or perforations that provide increased breathability, softness and a garment-like texture. The underwear-like appearance may be enhanced by substantially aligning the waist edge and the leg edge at the side seams 58 (see FIG. Figure 4 and 5 ).
[0158] The front band 54 and the rear band 56 may include graphics (see, for example, Figure 1The graphic may extend substantially around the entire perimeter of the absorbent article 10 and may be disposed across the side seams 58 and / or across the proximal front belt seam 15 and the rear belt seam 17; or alternatively, disposed adjacent the seams 58, 15 and 17 in the manner described in U.S. Pat. No. 9,498,389 to create a more underwear-like article. The graphic may also be discontinuous.
[0159] Alternatively, discrete side panels may be connected to the sides 22 and 24 of the chassis, rather than attaching belts 54 and 56 to the chassis 52 to form a pant. Suitable forms of pants including discrete side panels are disclosed in U.S. Pat. Nos. 6,645,190, 8,747,379, 8,372,052, 8,361,048, 6,761,711, 6,817,994, 8,007,485, 7,862,550, 6,969,377, 7,497,851, 6,849,067, 6,893,426, 6,953,452, 6,840,928, 8,579,876, 7,682,349, 7,156,833, and 7,201,744.
[0160] Top sheet
[0161] The top sheet 26 is the portion of the absorbent article 10 that contacts the wearer's skin. The top sheet 26 may be joined to a back sheet 28, an absorbent core 30, a barrier leg cuff 32, and / or a portion of any other layer as known to those of ordinary skill in the art. The top sheet 26 may be compliant, feel soft, and non-irritating to the wearer's skin. In addition, at least a portion or all of the top sheet 26 may be liquid permeable, allowing liquid body exudates to easily penetrate its thickness. Suitable top sheets 26 may be made of many various materials, such as porous foam, reticulated foam, open-cell plastic film, woven material, nonwoven material, natural fibers (e.g., wood fibers or cotton fibers), synthetic fibers or filaments (e.g., polyester fibers or polypropylene fibers or PE / PP bicomponent fibers or mixtures thereof), or a combination of natural fibers and synthetic fibers. The top sheet 26 may have one or more layers. The top sheet 26 may be open-cell ( Figure 2 , element 31), may have any suitable three-dimensional features, and / or may have a plurality of embossments (e.g., bonding patterns). Topsheet 26 may be hydrophilic or hydrophobic, or may have hydrophilic and / or hydrophobic portions or layers. If topsheet 26 is hydrophobic, then there will typically be holes to allow body exudates to pass through topsheet 26.
[0162] Top sheet 26 can have at least 15%, or at least 18%, or at least 20%, or at least 25% opacity, as determined according to the opacity test method described below.Especially if the urease inhibitor used in absorbent article of the present invention is neither white nor transparent, application has good opacity (such as at least 15%) of top sheet 26 to help reduce the visibility of urease inhibitor through top sheet 26.In fact, because urease inhibitor of the present invention is applied inside absorbent article, that is, neither on the body-facing surface of top sheet 26 nor on the surface facing clothes of back sheet, therefore urease inhibitor with certain non-white color can be used.If urease inhibitor is used on the body-facing surface of top sheet 26, then due to the presence of urease inhibitor, the body-facing surface of top sheet 26 will provide spotty and unsightly outward appearance.
[0163] The topsheet 26 of the absorbent article of the present invention may not contain a body lotion.
[0164] Negatives
[0165] Backsheet 28 is generally that part of the surface positioning facing clothes of absorbent article 10 adjacent to absorbent core 30. Backsheet 28 can be joined to the top sheet 26 of absorbent article, outer cover material 40, absorbent core 30 and / or the part of any other layer by any attachment method known to those skilled in the art. Backsheet 28 prevents or at least suppresses the body exudates absorbed and held by absorbent core 10 from soiling articles, such as sheets, underwear and / or clothes. Backsheet is liquid impermeable. Backsheet can for example be or include a thin plastic film, such as a thermoplastic film, and it has a thickness of about 0.012mm to about 0.051mm. Other suitable backsheet materials can include breathable materials, which allow steam to escape from absorbent article, while still preventing or at least suppressing body exudates from seeing through backsheet.
[0166] Outer cover material
[0167] The outer cover material (sometimes referred to as a backsheet nonwoven material) 40 may include one or more nonwoven materials joined to and covering the backsheet 28. The outer cover material 40 forms at least a portion of the garment-facing surface 2 of the absorbent article 10 and effectively "covers" the backsheet 28 so that no film is present on the garment-facing surface 2. The outer cover material 40 may include bonding patterns, apertures, and / or three-dimensional features. The outer cover material 40 may be a spunlace nonwoven material.
[0168] Absorbent core
[0169] As used herein, the term "absorbent core" 30 refers to that portion of the absorbent article 10 that is intended to store liquid that enters the absorbent article during use (and therefore generally has the greatest absorbent capacity) and contains absorbent material. Figure 9-11 In some cases, the absorbent material 72 may be positioned in a core bag or core wrap 74 (the core bag or core wrap is contained by the absorbent core). Depending on the specific absorbent article, the absorbent material may be profiled or not, especially along the longitudinal centerline. "Profiled" means that the absorbent material is not evenly distributed over the entire surface area of the absorbent core. The absorbent core 30 may include a core wrap, an absorbent material 72, and a glue encapsulated in the core wrap, and is essentially composed of these elements, or is composed of these elements. The absorbent material may include or be composed of: a) superabsorbent polymer particles and / or superabsorbent fibers, or b) a mixture of superabsorbent polymer particles and air felt, or c) only air felt, or d) a high internal phase emulsion foam, or e) a) to d) any combination. In some cases, the absorbent material may include at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or at most 100% superabsorbent polymer by weight of the absorbent material. In such cases, the absorbent material may be free of air felt, or at least mostly free of air felt. The absorbent core perimeter (which may be the perimeter of the core wrap) may define any suitable shape, such as, for example, a rectangular "T", "Y", "hourglass" or "dog bone" shape. Preferably, the absorbent core has a rectangular shape. The absorbent core perimeter having a generally "dog bone" or "hourglass" shape may taper along its width toward the crotch region 14 of the absorbent article 10.
[0170] See also Figure 9-11 , the absorbent core 30 may have areas of reduced thickness (wherein the term "reduced" includes areas of no thickness, i.e., areas without absorbent core material). The areas of reduced thickness may be areas with little or no absorbent material 72, where the body-facing surface of the core bag 74 may be joined to the garment-facing surface of the core bag 74. These areas with little or no absorbent material may be referred to as "channels" 76. These channels may embody any suitable shape, and any suitable number of channels may be provided. In other cases, although less preferred, the absorbent core may be embossed to create an impression of a channel. Figure 9-11 The absorbent core in is only an example absorbent core. Many other absorbent cores with or without channels are also within the scope of the present disclosure.
[0171] Barrier leg cuffs / leg elastics
[0172] See also Figure 1 and Figure 2For example, the absorbent article 10 may include one or more pairs of barrier leg cuffs 32 and one or more pairs of leg elastic members 34. The barrier leg cuffs 32 may be positioned laterally inboard of the leg elastic members 34. Each barrier leg cuff 32 may be formed by a piece of material that is bonded to the absorbent article 10 so that it can extend upward from the body-facing surface 4 of the absorbent article 10 and provide improved containment of body exudates near the junction of the torso and legs of the wearer. The barrier leg cuffs 32 are defined by proximal edges that are directly or indirectly bonded to the top sheet 26 and / or the back sheet and free end edges that are intended to contact the wearer's skin and form a seal with the wearer's skin. The barrier leg cuffs 32 may extend at least partially between the front waist edge 18 and the back waist edge 20 of the absorbent article 10 on opposite sides of the central longitudinal centerline 50, and may be present at least in the crotch region 14. The barrier leg cuffs 32 may each include one or more elastic members 33 (e.g., elastic strands or strips) near or at the free end edges. These elastic members 33 enable the barrier leg cuffs 32 to help form a seal around the legs and torso of the wearer. The leg elastic members 34 extend at least partially between the front waist edge 18 and the back waist edge 20. The leg elastic members 34 substantially enable portions of the absorbent article 10 adjacent the chassis side edges 22, 24 to help form a seal around the legs of the wearer. The leg elastic members 34 may extend at least in the crotch region 14.
[0173] Elastic waistband
[0174] See also Figure 1 and Figure 2 , the absorbent article 10 may include one or more elastic waistbands 36. The elastic waistbands 36 may be positioned on the garment-facing surface 2 or on the body-facing surface 4. As an example, a first elastic waistband 36 may be present in the front waist region 12 near the front waist edge 18, and a second elastic waistband 36 may be present in the back waist region 16 near the back waist edge 20. The elastic waistbands 36 may help seal the absorbent article 10 around the wearer's waist and at least inhibit body exudates from escaping the absorbent article 10 through around the waist opening. In some cases, the elastic waistband may completely surround the waist opening of the absorbent article.
[0175] Collecting Materials
[0176] See also Figure 1 , Figure 2 , Figure 7 and Figure 8At least one acquisition and distribution layer (ADL) 38 may be disposed between the top sheet 26 and the absorbent core 30, which may be present at least partially in the middle of the top sheet 26 and the absorbent core 30. The ADL includes an acquisition material, which is generally a hydrophilic material that provides significant wicking of body exudates. These materials can dehydrate the top sheet 26 and allow body exudates to quickly enter the absorbent core 30. The acquisition material of the ADL may include, for example, one or more nonwoven materials, foams, cellulosic materials, cross-linked cellulosic materials, air-laid cellulosic nonwoven materials, spunlace materials, or combinations thereof. Typically, one or more layers of the ADL may each have a width and length that is less than the width and length of the top sheet 26. The ADL may have one or more areas of reduced thickness (wherein the term "reduced" includes areas without thickness, i.e., areas without one, more than one, or all layers of the material of the ADL), such as channels, as described above with reference to the absorbent core 30 (including embossed patterns). The channels in the ADL may be aligned or misaligned with the channels in the absorbent core 30. In one example, the first layer of the ADL may include a nonwoven material and the second layer of the ADL may include a cross-linked cellulose material. The second layer of the ADL may be disposed between the first layer of the ADL and the absorbent core. The first layer of the ADL may be disposed between the top sheet and the second layer of the ADL.
[0177] Landing Zone
[0178] See also Figure 1 and Figure 2 , the absorbent article 10 may have a landing zone area 44 formed in a portion of the garment-facing surface 2 of the outer cover material 40. If the absorbent article 10 is fastened from front to back, the landing zone area 44 may be located in the rear waist region 16; or if the absorbent article 10 is fastened from back to front, the landing zone area may be located in the front waist region 12. In some cases, the landing zone 44 may be or may include one or more discrete nonwoven materials that are attached to a portion of the outer cover material 40 in the front waist region 12 or the rear waist region 16, depending on whether the absorbent article is fastened in the front or back. In essence, the landing zone 44 is configured to receive the fastener 46 and may include, for example, a plurality of loops configured to engage with a plurality of hooks on the fastener 46, or vice versa.
[0179] Wetting indicator / graphics
[0180] See also Figure 1, the absorbent article 10 of the present disclosure may include graphics 78 and / or wetness indicators 80 visible from the garment-facing surface 2. The graphics 78 may be printed on the landing zone 40, the backsheet 28, and / or other locations. The wetness indicators 80 are typically applied to the side of the backsheet 28 facing the absorbent core so that they can be contacted by body exudates within the absorbent core 30. In some cases, the wetness indicators 80 may form part of the graphics 78. For example, the wetness indicators may appear or disappear, and characters may be created / removed in some graphics. In other cases, the wetness indicators 80 may be coordinated (e.g., the same design, the same pattern, the same color) or not coordinated with the graphics 78.
[0181] Front and back ears
[0182] See above mentioned Figure 1 and Figure 2 , the absorbent article 10 may have a front ear 47 and / or a back ear 42 in a taped diaper. In most taped diapers, only one set of ear pieces is needed. A single set of ear pieces may include a fastener 46 configured to engage a landing zone or landing zone region 44. If two sets of ear pieces are provided, in most cases, only one set of ear pieces may have a fastener 46, while the other set of ear pieces does not have a fastener. The ear pieces or portions thereof may be elastic or may have an elastic sheet. In one example, an elastic film or elastic strand may be positioned between the first nonwoven material and the second nonwoven material. The elastic film may be apertured or may be non-apertured. The ear pieces may be molded. The ear pieces may be integral (e.g., an extension of an outer cover material 40, a backsheet 28, and / or a topsheet 26), or may be discrete components attached to the base structure 52 of the absorbent article on the body-facing surface 4, on the clothing-facing surface 2, or between the two surfaces 4, 2.
[0183] Masking layer
[0184] One or more masking layers or materials may be provided in the absorbent article 10. The masking layer may be a layer that provides a soft feel when the absorbent article is touched from the garment-facing surface 2 or the body-facing surface 4. The masking layer may "mask" the graininess potentially caused by the absorbent material 72 (such as superabsorbent polymer). The masking layer may "mask" body exudates so that they are not visible when viewing the body-facing surface 4 or the garment-facing surface 2 of the absorbent article 10. The masking layer may also mask the visibility of urease inhibitors. The masking layer may have a viscosity of about 15 g / m 2 About 50g / m 2 or about 15g / m 2 About 40g / m 2The masking layer may include one or more nonwoven materials (e.g., spunlace nonwoven materials), foams, pulp layers, and / or other suitable materials. The masking layer may be the outer cover material 40. The masking layer may be a layer that forms the garment-facing side or body-facing side of the core bag 74. The masking layer may be a separate material positioned between the garment-facing side of the core bag 75 and the liquid-impermeable backsheet 28.
[0185] Packing
[0186] The absorbent articles of the present disclosure may be placed in a package. The package may comprise a polymer film and / or other material. Graphics and / or markings associated with the characteristics of the absorbent articles may be formed, printed, positioned, and / or placed on an outer portion of the package. Each package may include a plurality of absorbent articles. The absorbent articles may be stacked under compression to reduce the size of the package while still providing a sufficient amount of absorbent articles for each package. By packaging the absorbent articles under compression, caregivers can easily handle and store the packages while also providing savings in distribution for the manufacturer due to the size of the packages.
[0187] series
[0188] "Collection" refers to a display of packages of disposable absorbent articles having different article configurations (e.g., different elastomeric materials [in composition and / or structure] in the side panels, side wings, and / or belt flaps, different graphic elements, different product structures, fasteners, or none of these). The packages may have the same brand and / or sub-brand and / or the same trademark registration and / or be made by or for a common manufacturer, and such packages may be available at a common point of sale (e.g., oriented to be adjacent to each other in a given area of a retail store). A collection is sold as a collection of products, which typically have similar packaging elements (e.g., type of packaging material, film, paper, primary color, design theme, etc.), which conveys to consumers that different individual packages are part of a larger collection. Collections often have the same brand, such as "Huggies", and the same sub-brand, such as "Pull-Ups". Different products in a collection may have the same brand "Huggies" and sub-brand "Little Movers". The differences between the "Pull-Ups" products in the series and the "Little Movers" products in the series may include product form, application method, different fastening design or other structural elements designed to address differences in physiological or psychological development. In addition, the packaging method is obviously different in that the "Pull-Ups" are packaged in a film bag that is mainly blue or pink, and the "Little Movers" are packaged in a film bag that is mainly red.
[0189] Further with respect to a "collection," as another example, a collection may be formed of different products having different product forms that are manufactured by the same manufacturer, e.g., "Kimberly-Clark," and have a common trademark registration, e.g., one product may have the brand name "Huggies," and a sub-brand such as "Pull-Ups." Different products in a collection may have the brand / sub-brand "Good Nites," and both are registered trademarks of The Kimberly-Clark Corporation and / or manufactured by Kimberly-Clark. Collections also typically have the same trademarks, including trademarks of the brand, sub-brands, and / or features and / or benefits of the entire collection. An "online collection" refers to a "collection" that is distributed through a common online source.
[0190] sanitary napkin
[0191] See also Fig.12 , the absorbent article of the present disclosure may be a sanitary napkin 110. The sanitary napkin 110 may include a liquid-permeable top sheet 114, a liquid-impermeable or substantially liquid-impermeable bottom sheet 116, and an absorbent core 118. The liquid-impermeable bottom sheet 116 may or may not be vapor-permeable. The absorbent core 118 may have any or all of the features described herein with respect to the absorbent core 30, and in some forms, may have a second top sheet 119 (STS) instead of the ADL disclosed above. The STS 119 may include one or more channels (including embossed patterns) as described above. In some forms, the channels in the STS 119 may be aligned with the channels in the absorbent core 118. The sanitary napkin 110 may also include wings 120 extending outwardly relative to the longitudinal centerline 180 of the sanitary napkin 110. The sanitary napkin 110 may also include a transverse centerline 190. The wings 120 may be joined to the top sheet 114, the bottom sheet 116, and / or the absorbent core 118. The sanitary napkin 110 may also include a front edge 122, a rear edge 124 longitudinally opposite the front edge 122, a first side edge 126, and a second side edge 128 longitudinally opposite the first side edge 126. A longitudinal centerline 180 may extend from the midpoint of the front edge 122 to the midpoint of the rear edge 124. A transverse centerline 190 may extend from the midpoint of the first side edge 128 to the midpoint of the second side edge 128. The sanitary napkin 110 may also have additional features commonly found in sanitary napkins as is known in the art.
[0192] Example cross section of an absorbent article
[0193] Figures 13 to 15 Example cross-sectional views of absorbent articles within the scope of the present disclosure are shown. Fig.13 is an exemplary cross-sectional view taken within the front waist region 12 of an absorbent article. Fig.14 is an exemplary cross-sectional view taken within the crotch region 14 of an absorbent article. Fig.15 1 is an exemplary cross-sectional view taken within the rear waist region 16 of an absorbent article. Figures 13 to 15 , the outer cover material is element 40, the top sheet is element 26, the back sheet is element 28, the absorbent core is element 30, the core bag is element 74, the absorbent material is element 72, and the ADL is element 86. ADL 86 may include a cross-linked cellulosic material and is optional. The acquisition material is element 88. The barrier leg cuffs are element 90. The elastic components in the barrier leg cuffs are element 92. The back ears are element 42. The fasteners on the back ears 42 are element 46. For clarity, the construction glue and / or bonds between the layers and / or components have been removed. Other cross-sectional configurations known to those skilled in the art are also within the scope of the present disclosure.
[0194] Biobased content of components
[0195] The components of the absorbent articles described herein may be at least partially composed of bio-based content, as described in U.S. Patent Application No. 2007 / 0219521A1. For example, superabsorbent polymer components may be bio-based via their derivation from bio-based acrylic acid. Bio-based acrylic acid and its production method are disclosed in U.S. Patent Application Publication No. 2007 / 0219521 and U.S. Patents 8,703,450, 9,630,901 and 9,822,197. Other components such as nonwovens and film components may include bio-based polyolefin materials. Bio-based polyolefins are further discussed in U.S. Patent Application Publication Nos. 2011 / 0139657, 2011 / 0139658, 2011 / 0152812 and 2016 / 0206774 and U.S. Patent No. 9,169,366. Exemplary bio-based polyolefins for use in the present disclosure include polymers available under the designations SHA7260™, SHE150™, or SGM9450F™ (all available from Braskem SA).
[0196] The absorbent article component may comprise a biobased content value of, for example, from about 10% to about 100%, from about 25% to about 100%, from about 40% to about 100%, from about 50% to about 100%, from about 75% to about 100%, or from about 90% to about 100%, as measured using ASTM D6866-10 Method B.
[0197] Recycling-friendly and bio-based absorbent products
[0198] The components of the absorbent articles described herein can be recycled for other uses, whether or not they are (at least partially) formed of recyclable materials. Examples of recyclable absorbent article materials are nonwovens, films, fluff pulp, and superabsorbent polymers. The recycling process can sterilize the absorbent articles using an autoclave, and then the absorbent articles can be shredded and separated into different by-product streams. Example by-product streams may include plastics, superabsorbent polymers, and cellulose fibers, such as pulp. These by-product streams can be used to produce fertilizers, manufacture plastic products, paper products, viscose, building materials, pets, or absorbent pads on hospital beds and / or other uses. More details about absorbent articles that are conducive to recycling, designs of recycling-friendly diapers, and designs of recycling-friendly and bio-based component diapers are disclosed in U.S. Patent Application Publication No. 2019 / 0192723, published on June 27, 2019.
[0199] Test Method
[0200] Urease activity test method
[0201] The urease activity test method measures the urease activity in absorbent articles treated with a test solution containing urease and synthetic urine containing urea. In this method, similar test samples cut from similar absorbent articles of interest are placed in test containers and treated with a test solution containing urease and synthetic urine containing urea. A collagen layer is also present in each test container. Each test container is sealed and incubated at 37°C for about 4 hours. Thereafter, the urease activity is characterized by measuring (a) gas phase ammonia release, (b) the pH of the topmost layer of the absorbent article sample (i.e., the body-facing layer of the absorbent article), and (c) the pH of the collagen.
[0202] Sample and material preparation
[0203] For each absorbent article of interest, a test sample was cut from each of six similar absorbent articles of interest. The test sample cut from each similar absorbent article of interest was a disk of 10.0 cm in diameter and centered at a point on the transverse centerline, the distance of which behind the front edge of the absorbent core of the absorbent article being 48.5% of the entire length of the absorbent core (i.e., in longitudinal dimension). That is, the point centered by each test sample was along the transverse centerline and slightly in front of the intersection of the transverse and longitudinal centerlines of the absorbent core. At this position, the disk was cut or punched through all layers present in the absorbent article, and the test sample subsequently maintained the internal organization of the layer structure as present in the complete absorbent article.
[0204] During and after the addition of the test solution, a cylindrical screw-top polypropylene container with a volume of about 500 mL, a diameter of about 10.5 cm, and a height of about 8 cm was used to hold each test sample. The bottom diameter of the cylindrical container was large enough so that the test sample could lie flat. A central hole with a diameter of 8 mm was drilled in each lid of the test container. The hole was immediately sealed with tape and opened only after the container was incubated at 37°C.
[0205] For each screw-top container used during analysis, a ring (made of acrylic or polycarbonate) with an outer diameter of 7.5 cm, an inner diameter of 5 cm, and a thickness of 7.5 mm was formed.
[0206] From commercially available collagen sheets (Naturin COFFI clear, with a thickness of 33.5 ± 0.4 g / m 2 A circular collagen disk with a diameter of 7.0 cm is cut from a 100 μm diameter ELISA kit (Viscofan Group, Tajonar, Spain) or equivalent to be positioned individually above each test sample. Each circular collagen disk is placed on top of the ring. This assembly allows the collagen disk to be positioned above each test sample without direct contact between the collagen disk and the test sample.
[0207] Synthetic urine was prepared by dissolving 2% w / w urea, 0.9% w / w sodium chloride, 0.11% w / w magnesium sulfate monohydrate, 0.079% w / w calcium chloride monohydrate in deionized water.
[0208] Prepare a urease stock solution (23.5 U / ml) by dissolving Jack Bean urease (Cat. No. U1500, Millipore Sigma, St. Louis, MO, USA, or equivalent) in deionized water.
[0209] For each sample to be tested, 75 ml of test solution was prepared immediately before use by mixing 67.5 ml of synthetic urine and 7.5 ml of urease stock solution at ambient laboratory temperature (23 ± 1 °C).
[0210] Test procedures
[0211] Each test sample is placed in the above-mentioned cylindrical screw-top container with the skin-facing side facing up. Then 75mL of test solution (prepared just before use) is poured on the test sample. Within one minute, after visually confirming that the test solution is completely absorbed by the test sample and there is no free liquid above the test sample, the ring carrying the single layer of collagen is placed above the test sample so that there is no direct contact between the collagen disk and the test sample. In the case where the free test solution remains visible in the test container after one minute, use an appropriate device such as a pipette to remove the free test solution and place the ring carrying the collagen layer above the test sample. Immediately close the test container with the container lid and culture the test container in a climate-controlled oven / incubator at 37°C for 4.0±0.25 hours.
[0212] Measurement and reporting
[0213] After the incubation period, the test container for each test specimen to be characterized was immediately removed from the oven / incubator and measured.
[0214] For each test container and test sample, the concentration of gas phase ammonia in the head space above the test sample in the test container is measured using a Draeger flow tube-based gas phase ammonia detection system (e.g., available from Draegerwerk AG & Co. KGaA, Luebeck, Germany). Suitable equipment for this particular application is a Draeger short-term detection tube-ammonia 5 / b (catalog number 81 01 941) and a Draeger Accuro pump (catalog number 64 00 000), or equivalent. Remove the tape sealing the orifice in the test container lid and insert the ammonia tube into the test container to a depth of 3 ± 0.5 cm. According to the manufacturer's instructions, use the Draeger pump to extract the gas phase sample in the test container, take 100 ml twice (i.e. 200 ml), and then divide the color change level by 2 to obtain the ppm value of ammonia. Depending on the concentration of ammonia in the head space, it may be necessary to use an alternative short-term ammonia detection tube suitable for the concentration to be measured. The level of color change in the ammonia tube is used to determine the amount (ppm) of ammonia in the gas phase of the container. For each test container and test sample, record the gas phase ammonia concentration to the nearest 1 ppm.
[0215] After measuring the gas phase headspace ammonia (about 30 minutes-60 minutes), for each test container and test sample, the lid of each test container is unscrewed and removed. The collagen disk and ring are taken out / pulled out from the test container to avoid contact between the collagen and the side of the container. The pH of the collagen layer is measured using a skin and scalp pH meter (catalog number HI981037, Hanna Instruments, Smithfield, RI, USA, or equivalent). Typically, collagen will form some viscosity and adhere to the ring during incubation, thereby supporting moderate pressure on the collagen surface. This allows the collagen to be supported on the ring when the pH probe contacts the collagen disk for pH measurement. Prior to measurement, the pH meter was calibrated with buffer solutions of pH 4 and 7 according to the manufacturer's instructions. The pH of the collagen associated with each test sample was recorded to an accuracy of 0.01 of the pH of the test sample collagen.
[0216] Finally, for each test sample, measure the pH of the topmost layer of the absorbent article test sample using a skin and scalp pH meter. When the pH meter is placed in contact with the topmost layer of the test sample, the entire test sample (all layers) remains intact beneath the topmost layer. Record the pH of the topmost layer of each test sample to the nearest 0.01 of the pH of the test sample topsheet.
[0217] Calculate the arithmetic mean of the gas phase ammonia concentrations in all the test samples analyzed and report them as the gas phase ammonia concentration of the sample absorbent article, accurate to 0.1 ppm. Calculate the arithmetic mean of the topsheet pH in all the test samples analyzed and report them as the topsheet pH of the sample absorbent article, accurate to 0.1.
[0218] The arithmetic mean of the collagen pH in all test samples analyzed is calculated and reported to the nearest 0.1 as the collagen pH due to the sample absorbent article.
[0219] Improved fluid collection test
[0220] The Modified Fluid Acquisition ("MFA") test is designed to measure the rate at which a 0.9 wt. % saline solution is absorbed into an absorbent article compressed at 2.07 kPa. Additional layers may be placed on top of and / or below the absorbent core for use in the "Modified Fluid Acquisition Test" (see Examples below), in which case the MFA measures the rate at which a 0.9 wt. % saline solution is absorbed into the absorbent core and the additional layers compressed at 2.07 kPa.
[0221] A known volume was introduced four times, with each subsequent dose starting five (5) minutes after the previous dose had been absorbed. The time required to absorb each dose was recorded. The test fluid was a 0.9 weight / volume % saline solution and was prepared as follows: 9.0 g ± 0.05 g of NaCl was weighed out into a weighing boat, transferred to a 1 L volumetric flask and diluted by volume with deionized water.
[0222] MFA equipment is shown in Figures 16 to 18B . The MFA apparatus includes a bladder assembly 3001 and a top plate assembly 3200 including a deposition assembly 3100. A controller 3005 is used to 1) monitor the impedance across the electrodes 3106 and record the time interval during which the 0.9 wt % saline solution is in the cylinder 3102; 2) connect to a liquid pump 3004 to start / stop dispensing; and 3) measure the time interval between dosing and dosing. The controller 3005 is capable of recording time events with an accuracy of ± 0.01 seconds. An indoor air source 3014 is connected to a pressure regulator 3006, which is capable of delivering air at an appropriate flow / pressure to maintain 2.07 kPa in the bladder assembly 3001. The liquid pump 3004 (Ismatec MCP-Z gear pump or equivalent purchased from Cole Palmer (Vernon Hills, IL)) is capable of delivering a flow of 10 mL-80 mL at a rate of 3 mL / s-15 mL / s, which is connected via a Tygon ® The conduit 3015 is attached to the stainless steel tube 3104 of the deposition assembly 3100 .
[0223] The bladder assembly 3001 is made of 12.7 mm Plexiglas with overall dimensions of 80 cm long by 30 cm wide by 10 cm high. A pressure gauge 3007 for measuring the pressure within the assembly and a pressure gauge 3006 for regulating the introduction of air into the assembly are installed through two holes on the right side. The bladder 3013 is assembled as follows: a 50 mm by 100 mm silicone diaphragm (0.02" thick, 20 Shore A durometer, purchased as part number 86435K85 from McMaster-Carr (Cleveland, OH)) is covered on the top of the box, leaving enough slack so that the membrane touches the bottom of the box at its center point. A flanged aluminum frame 3003 is fitted over the top of the membrane and secured in place using a mechanical clamp 3010.
[0224] When in position, the assembly should not leak under a pressure of 3.45 kPa. Use 5 cm by 30 cm by 1 mm front 3008 and back 3009 sample supports to anchor the sample. The absorbent core (optionally, with additional layers on the top and / or below) is attached to the top surface of the sample support by adhesive tape or mechanical "hook" fasteners. These supports can be adjusted along the length of the aluminum frame 3003 via a simple pin-hole system to adapt to absorbent cores of different sizes and correctly align their load points.
[0225] The top plate assembly 3200 is made of a 80 cm by 30 cm 12.7 mm Plexiglas sheet reinforced with an aluminum frame 3109 for increased rigidity. The plate has a 170 mm wide by 201 mm long cutout centered laterally on the plate 170 mm from the front of the plate 3201 for mounting the deposition assembly. In addition, the top plate has thirty-six (36) holes drilled therethrough such as Fig.18A The top plate assembly 3200 is connected to the bladder assembly 3001 via two hinges 3012. During use, the top assembly is closed onto the bladder assembly and locked into place using mechanical clamps 3011.
[0226] The deposition assembly 3100 fits into the top plate 3200 and includes 1) a liquid introduction cylinder 3102; 2) a curved surface 3101 at the load point of the absorbent core; and 3) electrodes 3106 for detecting fluid in the cylinder 3102. Detailed dimensions of the curved components are provided in FIG. 17A to FIG. 17E middle. Fig.17A A side view of a curved part. Fig. 17B An end view of the curved component. Fig. 17C Bottom view of the curved part. Fig.17D A bottom perspective view of the curved component. Fig.17E is a top perspective view of the curved part. The curved part can be milled or 3D printed. The top part of the introduction cylinder is a 50.8mm OD Plexiglas cylinder 3102 with a 38.1mm LD. It is adapted into the curved part to give the introduction cylinder an overall height of 100mm. The embedded electrodes extend from the connector on the upper surface of the curved part and terminate flush with the inner wall of the introduction cylinder, 2mm from the bottom of the cylinder. The two electrodes are positioned 180 degrees apart. The nylon screen 3107 is cut and attached flush with the bottom of the cylinder so that the sample cannot swell into the cylinder. In the immediate vicinity of the two electrodes, a 5mm semicircle is cut in the screen. As shown Fig.18AThe deposition assembly is shown inserted into the top plate so that the curved surface is flush with the bottom of the top plate assembly 3200. The top of the introduction cylinder 3102 has a loose fitting nylon top cap 3103. The top cap has a 6.35 mm outer diameter steel tube 3104 inserted through its center. When the top cap is in place, the bottom of the tube ends 20 mm above the screen 3107. The top cap also has air holes 3105 to ensure that negative pressure does not hinder the absorption rate.
[0227] Lay the absorbent core flat on a laboratory bench and identify the intersection of the longitudinal centerline and the load point (as defined in the table below).
[0228] Conditions for the modified fluid collection test:
[0229] Load point from the front of the core Surge volume Flow rate Delivery time The number of subsequent surges mm mL mL / s s 170 75 15 5 4
[0230] The end of the absorbent core intended to be placed toward the front end of the absorbent article (i.e., the front waist region of a diaper or pants) is attached to the top surface of the front sample plate 3008 by adhesive tape or mechanical "hook" fasteners, with the top sheet facing upward. For an absorbent core that is symmetrical along its transverse axis, it is irrelevant which end of the absorbent core is attached to the top surface of the front sample plate 3008. This placement is such that no portion of the absorbent core covers the plate. The sample plate 3008 is attached to the aluminum frame 3003 so that when the top plate assembly is closed, the load point of the absorbent core, which is sized (i.e., the size of the absorbent article in which the absorbent core is intended to be placed) (as defined in the above table) will be longitudinally and laterally centered within the cylinder 3102. Once it is again ensured that no portion of the absorbent core covers the plate, the end of the absorbent core intended to be placed toward the rear end of the absorbent article is fixed to the rear sample plate 3009 by adhesive tape or mechanical "hook" fasteners. The rear sample plate 3009 is then attached to the aluminum frame 3003 so that the absorbent core is taut but not stretched. The top plate assembly was closed and secured, and the bladder was inflated to 2.07 kPa ± 0.07 kPa. The pressure was maintained at this level during the complete loading sequence of the test.
[0231] The pump 3004 is primed for use and then calibrated to deliver the size-dependent volume and flow rate selected from the table above. The volume and flow rate must be within ± 2% of the target value. The top cap 3103 is placed into the barrel 3102. The controller 3005 is activated, which then delivers the first dose of 0.9 wt % saline solution. After the volume has been absorbed, the controller waits 5.0 minutes before adding the next dose. This cycle is repeated for a total of four doses. If the fluid leaks out of or around the article (i.e., not absorbed into the article), the test is terminated. In addition, if any acquisition time exceeds 1200 seconds, the test is terminated. The acquisition time is defined as the difference between the start time (i.e., when the 0.9 wt % saline solution is first introduced into the barrel and the conductive fluid completes the circuit between the electrodes) and the stop time (i.e., when the liquid has completely drained from the barrel and the circuit between the electrodes is disconnected). The acquisition time for each dose is recorded by the controller to the nearest 1.0 second. After the last dose is obtained, pressure is applied and maintained for an additional 10 minutes. The pressure relief valve 3016 is opened to depressurize the bladder and the sample is removed from the collection system.
[0232] For each absorbent core to be evaluated, a total of four (4) replicates were run in the same manner. The "Acquisition Time" (seconds) for each dose was calculated and reported as the arithmetic mean of the replicates, accurate to 1.0 second.
[0233] As described above, additional layers may be placed on top of the absorbent core prior to testing, such as a topsheet material and / or a layer used as an acquisition material in an absorbent article. Additionally, a liquid-impermeable polyolefin film may be disposed beneath the absorbent core, i.e. between the absorbent core and the sample plate.
[0234] Collagen rewetting test method after collection
[0235] This method requires a collagen film with a fixed height frit absorption (FHFA at 0 cm) between 0.48 g / g and 0.66 g / g and a FHFA at 20 cm between 0.15 g / g and 0.21 g / g, as measured according to the method described below. The collagen film also has a 31.5 + / - 3.5 g / m 2 Collagen films are available commercially under the trade name Naturin COFFI clear from Viscofan Group, 31192 Tajonar-Navarra, Spain, or equivalent materials having the characteristics and basis weights described above.
[0236] Prior to testing, the collagen membrane is prepared by, for example, cutting it into 90 mm (3.54 in) diameter circular sheets using a sample cutting device, and by equilibrating the membrane in the controlled environment of a test chamber (see Modified Fluid Acquisition Test Method) for at least 12 hours (forceps will be used for all handling of the collagen membrane).
[0237] At least 5 minutes but no more than 6 minutes after the last gush absorption performed in the Modified Fluid Acquisition Test Method described above, remove the cover plate and weight and carefully lay the test sample flat on the laboratory bench.
[0238] Four pre-cut and balanced pieces of collagen material 1810 are weighed to an accuracy of at least one milligram and then centered over the loading point of the article as defined in the Modified Fluid Acquisition Test Method and covered with a poly(methyl methacrylate) (PMMA) (e.g., Perspex ® ) is covered with a plate 1830 of 90 mm (3.54 in) diameter and approximately 20 mm (0.78 in) thickness. Carefully add a 15 kg weight (1850) (also centered). After 30 + / - 2 seconds, carefully remove the weight and Perspex again ® plate and re-weigh the collagen membrane (see Fig.19 system 1800).
[0239] The rewetting result is the moisture uptake of the collagen film expressed in mg. Four products of each selection were tested in this manner and the average rewetted amount was calculated.
[0240] Fixed Height Frit Absorption (FHFA) Test Method at 20cm and 0cm
[0241] The test is suitable for measuring the uptake of a material after 30 seconds under conditions of aspiration pressure of 20 cm or 0 cm of a fluid, such as a saline solution (0.9 wt % NaCl solution).
[0242] General device configuration
[0243] Fig. 20 The FHFA measurement apparatus 1900 is shown: a suitable fluid delivery reservoir 1921 with an airtight piston 1924 to allow air to be released during filling of the device. An open-ended glass tube 1922 with an inner diameter of 10 mm extends through a port 1925 in the top of the reservoir so that there is an airtight seal between the outside of the tube and the reservoir, which allows the required zero-level head of water to be maintained during the experiment regardless of the amount of liquid in the reservoir. The reservoir 1921 is provided with a delivery tube 1931 having an inlet at the bottom of the reservoir, a piston 1923, with an outlet via flexible plastic tubing 1926 (e.g. Tygon ®) is connected to the bottom 1932 of the sample holder funnel 1927. The fluid reservoir is securely held in place by means of a standard laboratory clamp 1913 and a suitable laboratory support 1912. The inner diameters of the delivery tube 1931, the stopcock 1923 and the flexible plastic tube 1926 enable the fluid to be delivered to the sample holder funnel 1927 at a sufficiently high flow rate that such flow rate is higher than the flow rate absorbed by the collagen sample under the experimental conditions and precludes the measured uptake from being limited by the flow rate of the fluid supplied by the equipment system. The reservoir 1921 has a capacity of approximately 1 liter. Other fluid delivery systems may be employed provided that they are capable of delivering fluid to the sample holder funnel 1927 maintaining a zero level of hydrostatic liquid pressure 1903 at a constant height throughout the experiment.
[0244] The sample holder funnel 1927 has a bottom connector with an inner diameter of 10 mm, a measuring component, and a chamber 1933 in which a frit 1928 is contained. The sample holder chamber is of suitable dimensions to accommodate the sample 1930 and the confining pressure weight 1929. The frit is sealed to the wall of the chamber 1933. The frit has pores of specific dimensions of 16µm-40µm (frit type is P 40 as defined by ISO 4793) and a thickness of 7mm.
[0245] The confining pressure weight 1929 is a cylinder having the same diameter as the sample size (6 cm) and a weight of 593.94 g in order to precisely apply a confining pressure of 2.06 kPa to the sample 1930. The sample holder funnel 1927 is precisely held in place by a standard laboratory clamp 1914 using a suitable laboratory support 1911. The clamp should allow easy vertical positioning of the sample holder funnel 1927 so that the top of the frit 1928 can be positioned at the following positions: a) the same height (+ / - 1 mm) as the bottom end 1904 of the open-ended glass tube 1922; and b) precisely 20 cm (+ / - 1 mm) above the bottom end 404 of the open-ended glass tube 1922. Alternatively, two separate clamps are positioned at the above-described configurations a and b, and the sample holder funnel is moved alternately from one to the other. During non-use, the instrument is maintained in proper operating conditions, with the sample holder funnel 1927 flooded with excess liquid to ensure proper wetting of the frit 1928, which should be completely below the liquid level. The sample holder funnel 1927 is also covered with an airtight cap (not shown) to avoid evaporation and thus changes in the salinity of the solution. During storage, the pistons 1923 and 1924 are also therefore closed to avoid evaporation, and the open-ended tube 1922 is hermetically sealed with a cap (not shown).
[0246] Sample preparation
[0247] During sample preparation, only forceps were used to touch the sample. 6 cm diameter discs were cut from the collagen material using any suitable die cutter. The sample was then stored in a closed container, such as a covered petri dish, and conditioned in the controlled environment of the testing room for at least 24 hours.
[0248] Materials used:
[0249] 0.9% saline solution by weight
[0250] FHFA equipment (as described above) Bubble level
[0251] Analytical balance with vent protection and resolution of ±0.001g.
[0252] funnel
[0253] tweezers
[0254] Timer
[0255] Experimental Configuration
[0256] Before starting the experiment:
[0257] 1) Remove the top cap of the open-ended tube 1922 and the top cap of the sample holder funnel 1927.
[0258] 2) Ensure that the stopcock 1923 is closed, open the stopcock 1924 to allow air to flow out of the liquid reservoir, as it is displaced by the liquid during the refilling phase. Refill the liquid reservoir 1921 with 0.9% saline solution through the top of the open-ended tube 1922 with the aid of a suitable device such as a funnel (not shown), and at the end of the filling, close the stopcock 1924.
[0259] If the liquid level is near the bottom 1904 of the open-ended tube 1922 during any experiment, the liquid reservoir must be refilled by repeating this step 2 before running the next sample.
[0260] 3) Remove the sample holder funnel 1927 from the laboratory clamp 1914 and remove excess liquid and discard.
[0261] 4) Manually hold the sample holder funnel 1927 so that the top of the frit 1928 is about 20 cm below the bottom end 1904 of the open-ended tube 1922, and carefully open the piston 1923 until the air-liquid interface in the open-ended tube 1922 reaches the bottom end 1904 and a small amount of bubbles escape from the tube 1922. The piston 1923 is closed at this point.
[0262] 5) Again the excess liquid now present in the sample holder funnel 1927 is disposed of and the system is now ready to start the measurement.
[0263] For measuring fixed height frit absorption (FHFA) at 20 cm , for each repetition:
[0264] 1) Position the sample holder on the clamp 414 so that the top of the frit 1928 is exactly 20 cm (+ / - 1 mm) above the bottom end 404 of the open-ended tube 1922. To ensure reliable measurements, check with the aid of a bubble level that the frit 1928 is perfectly level.
[0265] 2) Carefully remove any remaining liquid droplets on top of the frit with the help of filter paper of any other suitable material.
[0266] 3) Weigh the sample using an analytical balance with a resolution of ±0.001 g. When the reading on the balance is constant, record the “weight” as the “dry sample weight” (W D ), accurate to 0.001g.
[0267] 4) Use tweezers to carefully align the 4 sheets of collagen material on top of each other. Such a stack of 4 sheets of collagen is then referred to as a "sample". With the aid of tweezers, position the sample 1930 in the center of the sample holder, being particularly careful not to change the orientation and relative position of each of the layers of the collection system.
[0268] 5) Position the confining pressure weight 1929 centrally on the sample
[0269] 6) Open the piston 1923 for 30 + / - 1 seconds to allow liquid to flow into the sample, and then close again.
[0270] 7) Carefully remove the confining pressure weight 1929 and sample 1930 from the frit 1928 with the aid of tweezers.
[0271] 8) Weigh the sample 1930 using an analytical balance with a resolution of ± 0.001 g. When the reading on the balance is constant, record the "weight" as "20 cm sample weight" (W 20 ), accurate to 0.001g.
[0272] The measurement of the sample is now complete, and subsequent replicates can be measured by repeating the above steps. Once the series of experiments is terminated, about 1 cm of liquid is added to the sample holder funnel 1927 to completely submerge the frit 1928. All pistons are closed and the top cover is positioned according to the above storage conditions to avoid evaporation and ensure the reliability of subsequent measurements.
[0273] calculate:
[0274] The FHFA at 20 cm is defined as follows (FHFA 20 ):
[0275] FHFA 20 = (W 20 -W D ) / W D , and the unit is g / g.
[0276] For measuring fixed height frit absorption (FHFA) at 0 cm , for each repetition:
[0277] 1) Position the sample holder on the clamp 1914 so that the top of the frit 1928 is exactly 0 cm (+ / - 1 mm) above the bottom end 404 of the open-ended tube 1922. To ensure reliable measurements, check with the aid of a bubble level that the frit 1928 is perfectly level.
[0278] 2) Carefully remove any remaining liquid droplets on top of the frit with the help of filter paper of any other suitable material.
[0279] 3) Weigh the sample using an analytical balance with a resolution of ±0.001 g. When the reading on the balance becomes constant, record the “weight” as the “dry sample weight” (W D ), accurate to 0.001g.
[0280] 4) Using tweezers carefully align the 4 sheets of collagen material on top of each other. Such a stack of 4 sheets of collagen is then referred to as a "sample". With the aid of tweezers, position the sample 1930 in the center of the sample holder, being particularly careful not to change the orientation and relative position of each of the layers of the collection system. It is important that during the experiment, the top sheet facing side of each layer now faces downward in the direction of the glass frit 1928, thereby correctly reproducing the liquid flow entry direction.
[0281] 5) Position the confining pressure weight 1929 centrally on the sample
[0282] 6) The piston 1923 is opened for 30 + / - 1 seconds to allow liquid to flow into the sample, and then closed again.
[0283] 7) Carefully remove the confining pressure weight 1929 and sample 1930 from the frit 1928 with the aid of tweezers.
[0284] 8) Weigh the sample 1930 using an analytical balance with a resolution of ±0.001 g. When the reading on the balance becomes constant, record the “weight” as “0 cm sample weight” (W0) to the nearest 0.001 g.
[0285] The measurement of the sample is now complete, and subsequent replicates can be measured by repeating the above steps. Once the series of experiments is terminated, about 1 cm of liquid is added to the sample holder funnel 1927 to completely submerge the frit 1928. All pistons are closed and the top cover is positioned according to the above storage conditions to avoid evaporation and ensure the reliability of subsequent measurements.
[0286] calculate:
[0287] The FHFA at 0 cm (FHFA0) is defined as follows:
[0288] FHFA0=(W0-W D ) / W D And the unit is g / g.
[0289] IPRP Test Method
[0290] Permeability generally refers to the quality of a porous material that allows it to allow liquids or gases to pass through it, and is therefore generally determined by the mass flow rate of a given fluid through it. The permeability of an absorbent structure is related to the ability of the material to quickly acquire and transport liquid within the structure, both of which are key characteristics of absorbent articles. Therefore, measuring permeability is one measure by which a material's suitability for use in absorbent articles can be assessed.
[0291] The following test is suitable for measuring the In-Plane Radial Permeability (IPRP) of porous materials. The amount of saline solution (0.9% NaCl) flowing radially through an annular sample of the material at constant pressure is measured as a function of time.
[0292] The test was conducted at 23°C ± 2°C and 50% ± 5% relative humidity. All samples were conditioned in this environment for twenty-four (24) hours prior to testing.
[0293] The following equipment or its parts are Fig.21 and Fig. 22 Shown in.
[0294] IPRP Sample Holder 400 Fig.21 , and includes a cylindrical bottom plate 405 , a top plate 410 , and a cylindrical stainless steel weight 415 .
[0295] The top plate 410 includes a 9 mm thick, 70 mm outer diameter annular bottom plate 420 and a 150 mm long tube 425 fixed in the center thereof. The tube 425 has an outer diameter of 15.8 mm and an inner diameter of 12 mm. The tube is glued and fixed in a circular 16 mm hole in the center of the bottom plate 420 so that the lower edge of the tube is flush with the lower surface of the bottom plate, as shown in FIG. Fig.21 As shown. The bottom plate 405 and the top plate 410 are made of Lexan ®or equivalent. The stainless steel weight 415 has an outer diameter of 70 mm and an inner diameter of 15.9 mm so that the weight is a close sliding fit on the tube 425. The thickness of the stainless steel weight 415 is about 22 mm and is adjusted so that the total weight of the top plate 410 and the stainless steel weight 415 is 687 g ± 1 g to provide a confining pressure of 2.0 kPa during measurement.
[0296] The bottom plate 405 is about 25 mm thick and has two registration grooves 430 cut into the lower surface of the plate so that each groove spans the diameter of the bottom plate and the grooves are perpendicular to each other. Each groove is 1.5 mm wide and 2 mm deep. The bottom plate 405 has a horizontal hole 435 that spans the diameter of the plate. The horizontal hole 435 has a diameter of 8 mm and its central axis is 15 mm lower than the upper surface of the bottom plate 405. The bottom plate 405 also has a central vertical hole 440 with a diameter of 8 mm and a depth of 10 mm. The central hole 440 is connected to the horizontal hole 435 to form a T-shaped cavity in the bottom plate 405. The outside of the horizontal hole 435 is threaded to accommodate an elbow 445 attached to the bottom plate 405 in a watertight manner. One elbow is connected to a vertical transparent tube 460, which has a total height of 175 mm measured from the bottom of the bottom plate 405 (including the elbow 445) and an inner diameter of 6 mm. The tube 460 is scored with a suitable mark 470 at a height of 100 mm above the upper surface of the base plate 420. This is a reference for the fluid level to be maintained during measurement. The other elbow 445 is connected via a flexible tube to a fluid delivery reservoir 700 (described below).
[0297] A suitable fluid delivery reservoir 700 is provided in Fig. 22 . The reservoir 700 is located on a suitable laboratory jack 705 and has an airtight plugged opening 710 to facilitate filling the reservoir with fluid. An open-ended glass tube 715 with an inner diameter of 10 mm extends through a port 720 in the top of the reservoir so that there is an airtight seal between the outside of the tube and the reservoir. The reservoir 700 is provided with an L-shaped delivery tube 725 having an inlet 730 below the surface of the fluid in the reservoir, a stopcock 735, and an outlet 740. The outlet 740 is connected to the reservoir via a flexible plastic tube 450 (e.g., Tygon ® ) is connected to elbow 445. The inner diameter of delivery tube 725, stopcock 735 and flexible plastic tube 450 enables fluid to be delivered to IPRP sample holder 400 at a high enough flow rate to maintain the fluid level in tube 460 at the scribe mark 470 at all times during measurement. Reservoir 700 has a capacity of about 6 liters, although a larger reservoir may be required depending on sample thickness and permeability. Other fluid delivery systems may be used as long as they are capable of delivering fluid to sample holder 400 and maintaining the fluid level in tube 460 at the scribe mark 470 during measurement.
[0298] IPRP water collection funnel 500 Fig. 22 500 and includes a housing 505 having an inner diameter of about 125 mm at the upper edge of the funnel. The funnel 500 is configured so that liquid falling into the funnel is discharged quickly and freely from the spout 515. A bracket having a horizontal flange 520 surrounding the funnel 500 facilitates mounting the funnel in a horizontal position. Two integral vertical internal ribs 510 span the inner diameter of the funnel and are perpendicular to each other. Each rib 510 is 1.5 mm wide and the top surface of the rib is located in a horizontal plane. The funnel housing 500 and the ribs 510 are made of a suitable rigid material such as Lexan ® or equivalent, so as to support the sample holder 400. To facilitate the loading of the sample, it is advantageous that the height of the ribs is sufficient to allow the upper surface of the base plate 405 to be located above the funnel flange 520 when the base plate 405 is located on the ribs 510. A bridge 530 is attached to the flange 520 so that two digital calipers 535 are installed to measure the relative height of the stainless steel weight 415. The digital calipers 535 have a resolution of ± 0.01 mm within a range of 25 mm. A suitable digital caliper is a Mitutoyo model 543-492B or equivalent. Each caliper is interfaced with a computer to allow height readings to be recorded periodically and stored electronically on the computer. The bridge 530 has a circular hole with a diameter of 22 mm to accommodate the tube 425 without the tube contacting the bridge.
[0299] The funnel 500 is installed above the electronic balance 600. Fig. 22 The balance 600 has a resolution of ±0.01 g and a capacity of at least 1000 g. The balance 600 is also interfaced with a computer to allow the balance readings to be periodically recorded and stored electronically on the computer. A suitable balance is a Mettler-Toledo model MS6002S or equivalent. The collection container 610 is located on the balance tray so that liquid discharged from the funnel spout 515 falls directly into the container 610.
[0300] The funnel 500 is mounted so that the upper surface of the rib 510 is located on a horizontal plane. The balance 600 and the container 610 are positioned below the funnel 500 so that the liquid discharged from the funnel spout 515 falls directly into the container 610. The IPRP sample holder 400 is located in the center of the funnel 500, wherein the rib 510 is located in the groove 430. The upper surface of the bottom plate 405 must be completely flat and horizontal. The top plate 410 is aligned with the bottom plate 405 and rests on it. The stainless steel weight 415 surrounds the tube 425 and rests on the top plate 410. The tube 425 extends vertically through the center hole in the bridge 530. Two calipers 535 are firmly mounted to the bridge 530, wherein the feet rest on points on the upper surface of the stainless steel weight 415. The calipers are set to zero in this state. The reservoir 700 is filled with 0.9% saline solution and resealed. The outlet 740 is connected to the elbow 445 via a flexible plastic tube 450 .
[0301] Sample preparation
[0302] Remove the topsheet and optionally any layers of the ADL from the complete absorbent article
[0303] Keep the complete absorbent core. Can keep the backsheet to reduce the possibility of disintegration of the absorbent core and be easy to handle the sample (for example, if the absorbent core is wrapped by nonwoven web, then it may not be necessary). However, if the absorbent article has other parts between the backsheet and the absorbent core, the backsheet needs to be removed. In this case, all parts need to be removed so as to isolate the absorbent core. Use a die-cutting machine to cut samples from the absorbent core in a circular ring with an outer diameter of 70mm-R0 and an inner diameter of 12mm-Ri at each position. Cut out samples from the crotch area 14 and the back area of the absorbent core.
[0304] The annular sample 475 of the material to be tested has an outer diameter of 70 mm and an inner hole diameter of 12 mm. One suitable way to cut the sample is to use a die cutter with a sharp concentric blade.
[0305] The top plate 410 is raised enough to insert the sample 475 between the top plate and the bottom plate 405, with the sample centered on the bottom plate and the plates aligned. The piston 735 is opened and the fluid level in the tube 460 is set to the scribe mark 470 by adjusting the height of the reservoir 700 using the jack 705 and by adjusting the position of the tube 715 in the reservoir.
[0306] Saline solution was run through the sample to pre-swell for 30 minutes, ensuring that the column of liquid remained at the scribe mark 470.
[0307] After 30 minutes of pre-expansion and when the fluid level in tube 460 stabilizes at the dash mark 470, begin recording data from the balance and caliper by computer. The balance reading and elapsed time are recorded every 10 seconds for five minutes. The average sample thickness B is calculated from all caliper readings between 60 seconds and 300 seconds and is expressed in cm. The flow rate in grams per second is the slope calculated by a linear least squares regression fit of the balance readings (dependent variable) at different times (independent variable) considering only the readings between 60 seconds and 300 seconds.
[0308] The permeability k is then calculated by the following formula:
[0309] (1)
[0310] in:
[0311] k is the permeability (cm 2 );
[0312] Q is the flow rate (g / s);
[0313] ρ1 is the liquid density at 20°C (g / cm 3 );
[0314] µ is the viscosity of the liquid at 20°C (Pa·s);
[0315] R0 is the outer sample radius (cm);
[0316] R i is the inner sample radius (cm);
[0317] B is the average sample thickness (cm); and
[0318] Δp is the pressure drop (Pa) calculated according to the following formula:
[0319]
[0320] in:
[0321] Δh is the height of the fluid level in tube 460 from the top side of bottom plate 405 to mark 470; Δh is 10 cm +- 0.1 cm- (cm);
[0322] g is the acceleration constant (m / sec 2 ); and ρ1 is the liquid density (g / cm 3 ).
[0323] Opacity Test Method
[0324] Opacity and contrast ratio measurements were made using a 0° / 45° spectrophotometer suitable for making standard CIE L*a*b* color measurements, such as a Hunter ColorFlex EZ spectrophotometer (Hunter Associates Laboratory Inc., Reston, Virginia, USA) or equivalent. The diameter of the instrument's measurement port was 30 mm. The analysis was conducted in a chamber controlled at approximately 23°C ± 2°C and 50% ± 2% relative humidity.
[0325] The instrument was calibrated using standard black and white tiles provided by the instrument supplier according to the supplier's instructions. After calibration, the Y value of the standard white tile was measured and compared to its true value. The specified true Y value of the standard white tile is usually in the range of 83 to 85, and the difference from the true value should be 0.5 or less. The spectrophotometer was set to use the CIE XYZ color space with D65 standard illumination and a 10° observer.
[0326] If possible, measure the lower ADS before they are incorporated into the absorbent article. If this is not possible, care should be taken not to introduce any contamination or deformation to the test sample layer when the lower ADS is cut from the product during material removal from the other layers (if necessary, using a cryogenic spray such as Cyto-Freeze, Control Company (Houston, Texas)). Take five rectangular samples of the lower ADS so that the center of each sample corresponds to the location of the load point on the lower ADS and so that the length and width of each sample is greater than the smallest dimension of the head.
[0327] Place the lower ADS sample flat on the instrument with the outward-facing surface toward the measurement port of the spectrophotometer and the center of the lower ADS sample (which corresponds to the load point of the lower ADS) matches the center of the port. The sample is further positioned so that there are no tears, holes or holes in the measurement port. Place a white standard tile on the opposite surface of the sample so that it completely covers the portion of the sample above the measurement port. Take a reading of the XYZ values and record each value to the nearest 0.01. Without moving the sample, remove the white plate and replace it with a black standard plate. Take a second reading of the XYZ values and record each value to the nearest 0.01.
[0328] Opacity is calculated by dividing the Y value measured using a black tile as a backing by the Y value measured using a white tile as a backing and then multiplying the ratio by 100.
[0329]
[0330] Five lower ADS samples were analyzed in this manner and the opacity of each sample was recorded. The arithmetic mean of the individual sample results was calculated and reported as opacity in percent to the nearest 1%.
[0331] The dimensions and values disclosed herein should not be understood as being strictly limited to the exact numerical values cited. Instead, unless otherwise indicated, each such dimension is intended to represent the stated value and a functionally equivalent range around that value. For example, a dimension disclosed as "40 mm" is intended to mean "about 40 mm".
[0332] Unless expressly excluded or otherwise limited, each document cited herein, including any cross-referenced or related patent or patent application and any patent application or patent to which this application claims priority or the benefit of, is hereby incorporated by reference in its entirety. The citation of any document is not an admission that it is prior art to any of the present invention disclosed or claimed herein, or an admission that it, by itself or in combination with any one or more of the references, proposes, suggests, or discloses any such invention. In addition, to the extent that any meaning or definition of a term in this invention conflicts with any meaning or definition of the same term in a document incorporated by reference, the meaning or definition assigned to that term in this invention shall govern.
[0333] Although the content of the present disclosure has been illustrated and described with specific embodiments, it is obvious to those skilled in the art that many other changes and modifications can be made without departing from the spirit and scope of the present disclosure. Therefore, all such changes and modifications within the scope of the present disclosure are consciously included in the appended claims.
Claims
1. An absorbent article (10), comprising: a liquid permeable top sheet (26), a liquid-impermeable backsheet (28), an absorbent core (30), and optionally at least one acquisition and distribution layer (38); wherein the absorbent core (30) is disposed between the top sheet (26) and the back sheet (28); and optionally at least one acquisition and distribution layer (38) is disposed between the top sheet (26) and the absorbent core (30); The absorbent article (10) comprises a polyol and a urease inhibitor.
2. The absorbent article (10) according to claim 1, wherein the urease inhibitor is dissolved and / or suspended in the polyol to form a suspension and / or solution comprising the urease inhibitor and the polyol.
3. The absorbent article (10) according to any one of claims 1 or 2, wherein the urease inhibitor is a natural urease inhibitor.
4. The absorbent article (10) according to claim 3, wherein the natural urease inhibitor is selected from the group consisting of green tea, extracts from green tea, grape seeds, extracts from grape seeds, and combinations thereof.
5. The absorbent article (10) according to any one of claims 1 to 4, wherein the polyol is miscible with water and is non-toxic.
6. The absorbent article (10) according to any one of the preceding claims, wherein the polyol has a boiling point of at least 100°C at atmospheric pressure.
7. The absorbent article (10) according to any one of the preceding claims, wherein the polyol is a diol or triol having 2 to 5 carbon atoms, preferably glycerol.
8. The absorbent article (10) according to any one of the preceding claims, wherein the weight ratio of the total amount of polyols to the total amount of urease inhibitors is from 10:1 to 1:
4.
9. The absorbent article (10) according to any one of the preceding claims, wherein the liquid permeable top sheet (26) has a first surface and a second surface opposite to the first surface, said first surface of said topsheet (26) and optionally at least one optional acquisition and distribution layer (38) being disposed between said second surface of said topsheet (26) and said absorbent core (30); wherein one or more of the following comprises the polyol and the natural urease inhibitor: i) the first surface of the top sheet (26), ii) said optional at least one acquisition and distribution layer (38), and iii) the absorbent core (30).
10. The absorbent article (10) according to any one of the preceding claims, wherein said at least one acquisition and distribution layer (38) comprises a part, preferably a major part or even the total amount of said urease inhibitor and / or said polyol comprised by said absorbent article (10).
11. A method for preparing an absorbent article (10), the method comprising the following steps: a) suspending and / or dissolving a urease inhibitor in a polyol to form a suspension and / or solution comprising the urease inhibitor and the polyol; b) applying the suspension and / or solution to one or more of the following a liquid permeable top sheet (26), an absorbent core (30), and at least one acquisition and distribution layer (38); c) assembling the absorbent article (10) such that the absorbent core (30) is disposed between the topsheet (26) and the backsheet (28); and at least one optional acquisition and distribution layer (38) is disposed between the topsheet (26) and the absorbent core (30).
12. The method according to claim 11, wherein the suspension and / or solution is applied to the at least one acquisition and distribution layer (38).
13. A method according to claim 11, wherein during assembly of the absorbent article (10), the suspension and / or solution is applied to a fiber web and / or thread arranged between the absorbent core (30) and the at least one acquisition and distribution layer (38) or as part of the at least one acquisition and distribution layer (38).
14. The method of claim 12, wherein the at least one acquisition and distribution layer (38) comprises at least a first layer and a second layer; and wherein the fiber web and / or threads are disposed between the first layer and the second layer.
